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Guillain-Barré syndrome
Guillain-Barré syndrome (GBS) is a heterogeneous post-infectious immune-mediated 
polyneuropathy, characterized by an acute flaccid paralysis and loss of  deep tendon 
reflexes. The clinical entity was described for the first time by Jean-Baptiste Octave 
Landry in 1859.1 In 1916, Georges Guillain, Jean-Alexandre Barré and André Strohl 
reported patients with an acute ascending paresis with an increased protein level 
with normal cell count in the cerebrospinal fluid (CSF).2 Since that year, the entity is 
referred to as GBS. The last few decades research groups focused on the important 
role of  antecedent infections and the immune system in the pathogenesis of  GBS. 
Pathogen-derived factors as well as host factors are likely to be involved in determining 
whether a person develops GBS after a common infection. This thesis focuses on the 
contribution of  genetic host factors in the pathogenesis of  GBS.
Diagnosis, course and treatment
The diagnosis of  GBS is mainly based on its clinical characteristics: a progressive 
symmetric muscle weakness in more than one limb in combination with a loss or 
decrease of  tendon reflexes. A variety of  other clinical signs and symptoms, such as 
sensory and/or cranial deficits and autonomic dysfunction can occur. Most patients 
have an increased protein level in CSF by the second week of  disease, but this is not 
required to confirm the diagnosis (see Appendix 1).3
The maximum level of  weakness in GBS patients by definition should be reached 
within 4 weeks. The maximum weakness is also called the nadir. Two to four weeks 
after the patients reach their nadir, spontaneous recovery usually starts. Recovery, 
however, can take months and many patients have residual deficits. 
Monitoring the respiratory capacity and autonomic functions of  GBS patients is 
of  great importance to prevent severe complications or even death by respiratory 
or autonomic dysfunction. The mortality rate of  GBS is about 2-5%. Besides 
general supportive care, immune-modulating therapy helps to improve patients 
who are severely affected (unable to walk unaided). Several randomized controlled 
trials reported a beneficial effect on outcome by plasma exchange and intravenous 
immunoglobulins (IVIg).4-7 A recent trial demonstrated that the combination of  IVIg 
and methylprednisolone might be superior in those patients who are in the first two 
weeks of  disease and unable to walk unaided and who have no contra-indication for 
the use of  high dose steroids.8
Incidence/Epidemiology
GBS is the most common cause of  a flaccid paralysis in the Western world. In 
The Netherlands, about 200 new cases are diagnosed per year (incidence rate 1.18/
100.000/year).9 GBS may affect persons of  all ages, but the incidence slightly increases 
with age and GBS is slightly more common in males than females. Although some 
studies have indicated that GBS tends to occur more often during the colder months, 
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seasonal variation in general is not reported. Two exceptions are: a higher incidence of  
GBS in summer occurs in Northern-China,10 and during the wet season in Curaçao.11
Heterogeneity of Guillain-Barré syndrome
Clinical features
GBS is a very heterogeneous disorder with respect to the severity and extent of  clinical 
features and the prognosis. Some patients have a mild weakness of  distal extremities, 
which recovers spontaneously without residual deficits. Other patients develop within 
a day a rapidly progressive weakness leading to tetraparalysis, ophthalmoplegia, diplegia 
facialis, bulbar weakness or respiratory deficiency for which they need ventilation and 
long term treatment in intensive care units and later in rehabilitation centers. The 
patients also vary with respect to the peripheral nerves involved, i.e. the extent of  
sensory deficits and cranial nerve involvement. This is also illustrated by the presence 
of  some variants of  GBS.  Some patients have only distal weakness, while others have 
facial or bulbar weakness. Other patients have a clinical triad of  ophthalmoplegia, 
areflexia and ataxia referred to as Miller-Fisher syndrome (MFS).12 Some patients may 
have minor symptoms and other patients may need respiratory support (20-30%).9, 13 
Although GBS is considered to be a self-limiting disorder, most patients have residual 
deficits. Only about 35% of  the patients fully recover, 35% have a mild handicap 
and about 30% remain with a severe handicap during years of  follow-up.14 Moreover, 
about 80% of  the patients who have neurologically well recovered complain about 
severe fatigue.15 This clinical heterogeneity makes it difficult to predict to what extent 
the patient will be disabled, both during the acute phase of  disease and during long-
term follow-up.
Electrophysiology
Electrophysiological characteristics are also diverse. Some patients have a reduced 
conduction velocity and partial conduction block indicative of  a demyelinating form 
of  GBS, while others have a reduction in distally evoked compound muscle action 
potentials with relatively spared conduction velocity in combination with other features 
of  an axonal form of  GBS.16 Moreover, results of  a single-fiber electrodiagnostic 
examination (EMG) study surprisingly indicated that the neuromuscular junction may 
also be involved in the pathophysiology of  GBS.17
Patients fulfilling the electrophysiological criteria of  demyelination are referred 
to as having acute inflammatory demyelinating polyneuropathy (AIDP), which is 
the most common form of  GBS in the Western-world (56-87%).16 Patients fulfilling 
the electrophysiological criteria of  an axonal degeneration without demyelination are 
referred as having an acute motor axonal neuropathy (AMAN) or an acute motor-
sensory axonal neuropathy (AMSAN) when sensory deficits are also present. These 
forms of  GBS are most frequently found in Chinese and Japanese GBS patients, but 
also in patients from Central-America and India.18, 19 Axonal degeneration can also 
occur secondary to severe demyelination.
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Pathology
Multifocal and segmental infiltration with predominantly macrophages in spinal roots 
and peripheral nerves has been shown in cases with primary demyelination (AIDP). 
The macrophages invade and strip off  the myelin sheaths.20 Complement deposits 
can be found on the outer membrane of  the Schwann cell.21 In severe cases, the axon 
degenerates as well. In the case of  primary axonal damage (AMAN), the macrophages 
are present under an intact myelin layer and complement depositions are present on 
the axolemma of  the motor fibres with minimal mononuclear infiltration.20, 22
Pathogenesis of Guillain-Barré syndrome
Antecedent infections
GBS is a typical post-infectious disorder. About 2/3 of  the patients report an upper 
respiratory tract infection (URTI), diarrhea or influenza-like symptoms one to three 
weeks prior to the onset of  weakness. The monophasic course of  GBS also illustrates 
the role of  infections. The most commonly found pathogens are Campylobacter jejuni, 
cytomegalovirus (CMV), Epstein-Barr virus (EBV), Mycoplasma pneumoniae and 
Haemophilus influenzae.23, 24 Although several case-reports have suggested that GBS 
in some patients is provoked by the administration of  a ganglioside mixture, certain 
vaccinations, pregnancy, surgery or cancer, these relations are anecdotal.25 The delay 
between infection and onset of  symptoms suggests that not the infection itself  but the 
immune response to the infectious agent plays a role in the pathogenesis of  GBS. In 
addition there is no evidence for direct infection of  the peripheral nerves.
Anti-ganglioside antibodies 
Antibodies directed to gangliosides can be detected in serum from subgroups of  GBS 
patients. Gangliosides are glycosphingolipids consisting of  a ceramide moiety, that is 
anchored in the plasma membrane and a sialic acid containing oligosaccharide, which is 
located extracellularly.26 Gangliosides are widely distributed and abundantly expressed 
in neuronal plasma membranes and play a role in cell growth and differentiation.27 
Most antibodies directed to these gangliosides are not only present in serum from 
GBS patients, but can also be found in low titers in serum from healthy controls and 
in a variety of  patients with other neurological or autoimmune disorders.28 In serum 
from healthy controls these antibodies generally are of  the IgM isotype suggesting that 
they belong to the naturally occurring antibody repertoire.29 These antibodies may play 
a role in first line defense against invading pathogens. With increasing age low titers 
of  IgG anti-ganglioside antibodies, usually directed to asialo-glycolipids, may also be 
present in healthy controls.30
In GBS patients the anti-ganglioside antibodies are usually of  the IgG1, IgG3 or 
IgA isotype, indicating a mucosal origin.31 Isotype switching is usually the result of  a 
cognate interaction between T-helper cells and B-cells. However, this might not be the 
case for polysaccharide antigens, as these are generally regarded as T-cell independent 
antigens. Interestingly, a recent paper showed that cross-linking of  pattern recognition 
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receptors (PPR) and B-cell receptors can induce isotype switching without T-cell 
help.32 
Whether anti-ganglioside antibodies are pathogenic in GBS is still a matter of  
debate, but there are several arguments favoring a pivotal role of  these antibodies: 
(i) Anti-ganglioside antibodies are found consistently in serum from a subgroup of  
GBS patients.33 In MFS patients, IgG anti-GQ1b antibodies are highly specific 
and can be found in up to 95% of  these patients.19 Other anti-ganglioside 
antibodies are also related with specific clinical entities (Table 1). For example, 
anti-GM1/GM1b/GD1a/GalNac-GD1a antibodies are associated with a 
pure motor variant of  GBS.31, 34, 35 Moreover, different subclasses of  anti-
ganglioside antibodies are associated with different clinical outcomes. In the 
case of  anti-GM1 antibodies, IgG1 is associated with diarrhea and a preceding 
C. jejuni infection and a slow recovery, while IgG3 is associated with an upper 
respiratory tract infection and rapid recovery.36 The IgG3 anti-GM1 antibodies 
are likely to be evoked by a preceding H. influenzae infection.37 
(ii) The titer of  anti-ganglioside antibodies generally decreases with clinical 
recovery, but sometimes remains high despite clinical recovery.38, 39
(iii) Anti-ganglioside antibodies are able to bind to nodes of  Ranvier, myelin, dorsal 
root ganglion cells, motor neurons and perisynaptic Schwann cells.40-44
(iv) Anti-ganglioside antibodies are able to fix complement. Moreover, the IgG1 
and IgG3 subclasses are capable of  activating the complement system.28, 45 
(v) Anti-ganglioside antibodies are capable of  inducing leucocyte degranulation 
and phagocytosis via Fcγ receptor mediated mechanisms.46
(vi) Anti-ganglioside antibodies can block ion-channel function and disturb 
neuromuscular transmission.47, 48
(vii) Anti-ganglioside antibodies can impair the function of  the blood-nerve barrier 
in an in vitro model.49
(viii) Passive transfer of  human and rabbit anti-GM1 by intra-neural injection results 
in axonal degeneration.50
(ix) Active immunization with gangliosides GM1, GD1a, GD1b induces an 
immune-mediated neuropathy with neurological deficits in rabbits.51 
Besides these anti-ganglioside antibodies, other components of  the immune 
response are also involved (Figure 1). The interaction between antigen presenting cells 
(APC), T-cells and B-cells will eventually lead to the production of  these antibodies. 
Macrophages which are present in the peripheral nerve infiltrates seem to play an 
important role in (i) promotion of  inflammation by releasing pro-inflammatory 
cytokines, (ii) destruction of  nerve tissue and also in (iii) remyelination and axonal 
regeneration.52 The pro-inflammatory cytokines and other mediators are likely to be 
involved the immune response, blood-nerve barrier breaching, demyelination and 
remyelination.53
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Figure 1. Pathogenesis of Guillain-Barré syndrome.
Upon infection the immune system is activated to eradicate the invading pathogen, in which antigen-
presenting cells (APC), T- and B-cell interactions are of  major importance. In GBS patients, however, the 
immune response is not only directed to the pathogen, but also to structures present on the peripheral 
nerves, the so-called gangliosides, which mimic those on infectious agents (molecular mimicry). Within 
the peripheral nervous system macrophages and complement factors play an important role in tissue 
destruction causing a polyneuropathy.
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Table 1. Relation between antecedent infection, anti-ganglioside antibodies and 
clinical features in GBS. 
Antecedent infection Antibodies to Clinical features
Campylobacter jejuni GM1, GM1b, GD1a rapidly progressive, pure motor variant 31, 34, 35, 110
 GalNac-GD1a  
 GQ1b, GT1a Miller Fisher syndrome oculomotor weakness   
  in GBS patients 111
Cytomegalovirus GM2 severe motor and sensory deficits
  high frequency of  respiratory insufficiency 112
Epstein-Barr virus not known autonomic dysfunction in one case-report 113
Mycoplasma pneumoniae Galactocerebroside mild form 9
Haemophilus influenzae GM1 pure motor variant, favorable outcome 23
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Molecular mimicry
In the last decade an intriguing concept of  molecular mimicry in GBS has been 
postulated, indicating a clear relation between antecedent infection and production of  
anti-ganglioside antibodies. Molecular mimicry is the mechanism by which infections 
trigger cross-reactive antibodies or T-cells that cause the symptoms of  autoimmune 
diseases. One way to prove a role for molecular mimicry is the identification of  
antibodies or T-cells that recognize both pathogen and host.54 In GBS several lines of  
evidence support the concept of  molecular mimicry:
(i) The strong epidemiological association between distinct acute infectious 
diseases and GBS.19
(ii) The strong association between specific types of  antecedent infections and 
specific types of  anti-ganglioside antibodies (Table 1).
(iii) Lipo-oligosaccharide (LOS) fraction of  the outer cell wall of  C. jejuni contains 
structures that mimic gangliosides. This mimic is consistent with the antibodies 
to gangliosides in patients in whom the C. jejuni was isolated.55
(iv) The anti-ganglioside antibodies cross-react with C. jejuni. The molecular 
mimicry of  the infectious agent therefore determines to a large extent cross-
reactive antibodies and the clinical features of  the patient.33
(v) Immunization of  animals with C. jejuni or purified LOS results in antibodies to 
LOS that cross-react with gangliosides. The antibody specificity is in accordance 
with the anti-ganglioside antibodies in serum from the patient from who the 
C. jejuni was isolated.48, 56
(vi) In case of  immunization of  Japanese white rabbits not only the cross-reactive 
antibody response is present, but also clinical, electrophysiological and 
histopathological features resembling GBS.50
Hence, it was postulated that GBS is a true case of  molecular mimicry.57
The above-mentioned arguments focus on molecular mimicry in the case of  preceding 
C. jejuni infection. However, molecular mimicry seems also to be present in the case of  
a preceding CMV or M. pneumoniae infection. The anti-ganglioside antibodies in CMV-
infected patients seem to be evoked by antigens that are induced by a CMV infection 
and cross-react with GM2 gangliosides.58 The anti-galactocerebroside antibodies 
present in M. pneumoniae infected patients seem to be induced by M. pneumoniae 
antigens.59 In the case of  a preceding H. influenzae infection, the anti-GM1 antibodies 
present in sera from GBS patients or the anti-GQ1b or anti-GT1a antibodies present 
in MFS-patients seem to be evoked against epitopes present on H. influenzae.60, 61
Several research groups tried to identify differences between GBS or MFS-related 
C. jejuni strains and C. jejuni from patients with an uncomplicated gastro-enteritis to 
assess whether pathogen-derived factors are necessary for the presence of  ganglioside-
mimicking epitopes. Differences between GBS or MFS related C. jejuni strains and 
C. jejuni from patients with an uncomplicated gastro-enteritis are:
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(i) The Penner serotyopes 19 and 41 were more frequently found in GBS-related 
strains than in control isolates from patients with uncomplicated gastro-enteritis 
in North-China62 and Japan63 respectively South Africa.64 This predominance of  
some Penner serotypes was not found in C. jejuni isolated from Dutch/ Belgium 
patients indicating geographical differences.65
(ii) Ganglioside-like structures are more frequent in C. jejuni isolates from GBS 
patients compared to controls.45, 66
(iii) Genes involved in LOS biosynthesis are clustered in the LOS biosynthesis gene 
locus (LOS locus). GBS-related C. jejuni strains are associated with a class A 
LOS locus, MFS-related C. jejuni strains with a class B LOS locus and strains of  
an uncomplicated gastroenteritis with a class C LOS locus.67
(iv) The putative LOS-modifying sialic acid transferase-II encoding gene cstII that is 
required for the synthesis of  a GQ1b-like epitope is over-represented in GBS-
related strains.68
(v) Immunization of  mice with C. jejuni strains in which genes involved in sialylation 
of  LOS (cstII and orf10/orf11) were knocked-out shows that these mice did not 
develop anti-GD1a antibodies, but only asialo-GM1 antibodies that are not 
associated with the development of  GBS.69
These results indicate that genes involved in sialylation of  LOS are crucial for the 
induction of  cross-reactive antibodies. However, the above-mentioned associations 
are not absolute. Host factors are also involved in determining whether a person 
develops GBS after an encounter with a C. jejuni strain expressing ganglioside-
mimicking epitopes. These host factors are the main topic of  this thesis.
Host factors
Host factors are likely to (partially) confer susceptibility to the development of  GBS 
or its clinical course upon infection, since:
(i) GBS rarely occurs after an infection with the agents frequently reported in 
GBS. Only 1 individual per 1000 infected persons develops GBS after a C. jejuni 
enteritis.70 Although epidemics of  C. jejuni have been reported, these outbreaks 
were not followed by an epidemic of  GBS.71
(ii) One case report showed that in a family with an outbreak of  C. jejuni enteritis, 
only one member developed GBS. This person was the only one who had high 
titers of  anti-ganglioside antibodies.72
(iii) The estimated recurrence rate of  GBS is about 1 to 5%, which shows a 10- 
to 50-fold increased risk compared to the risk for developing GBS for a first 
time.73
(iv) The clinical characteristics of  GBS patients are even heterogeneous within 
subgroups of  patients with the same type of  antecedent infection.
(v) Although prognostic models of  GBS have been reported, they have a limited 
predictive value. Independent predictors of  poor outcome (inability to walk 
independently) are a preceding gastro-intestinal illness, older age (>50 years), a 
low MRC-sumscore and a recent CMV infection.74
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(vi) Seven previously published reports showed the occurrence of  GBS within 
families.75-81 Siblings were affected in three families, and parent and child 
were affected in four families. Clustering of  a disease in families is generally 
suggestive for a genetic component in the development of  the disease.
(vii) Several groups have studied the highly polymorphic human leucocyte antigen 
(HLA)-alleles in groups of  patients with GBS to assess whether HLA-antigens 
confer susceptibility for developing GBS or the clinical pattern of  a specific 
subgroup. Some studies indicated that certain HLA antigens are a susceptibility 
factor for developing GBS or are related to specific clinical or serological 
subgroups (reviewed and discussed in Chapter 4.1).82-98 In recent years some 
groups studied other genetic polymorphisms involved in regulating the immune 
response and their results are encouraging (Table 2).99-104
Table 2. Population-association studies of immune-response genes in GBS other 
than HLA.*
polymorphism(s) ethnic origin group size (n) reported association
  population (GBS vs controls)    
TNF-α Japanese 81 vs 85  TNFα 2-allele increased in C. jejuni + GBS  
   patients vs controls (p=0.01)99
      
Fc-gamma receptors Caucasian 31 vs 187 Fcγ-RIIA 131 H/H increased in
(Fc-gammaR-IIA,    GBS patients vs controls (OR 2.45, 
-IIIA, -IIIB)   p=0.037)
   Fcγ-RIIA 131 H/H associated with
   severe disease (F-score 4 & 5; OR 18.6, 
   p=0.007)100
      
 Caucasian 62 vs 89 Fcγ-RIIIb NA1/NA1 associated 
   with a mild form of  disease (p=0.027)101
IL-10    
(-1082G/A, -819T/C, Caucasian 87 vs 87 CC homozygotes at position -819 and
  -592 A/C)    -592 significantly more frequent in GBS
   patients versus controls  (p=0.027)102
      
KM (kappa light  Caucasian 83 vs 196 KM3/KM3 increased in GBS patients vs
chain of  Ig)    controls (OR 2.3, p=0.01)
   KM1/KM3 decreased in GBS patients vs 
   controls (OR 0.4, p=0.01)103
ApoE  Caucasian 91 vs 169/406 no association104
*Reports studying HLA-alleles in GBS are reviewed in Chapter 4.1. GBS: Guillain-Barré syndrome, 
TNF-α: tumor necrosis factor alpha, IL-10: interleukin 10, ApoE: apolipoprotein- E.
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This thesis focuses on the contribution of  genetic susceptibility factors in the 
pathogenesis of  GBS.
Genetic approaches
Generally, there are two different approaches to study whether there is a genetic 
susceptibility for the development of  a disease; whole genome screens and candidate 
gene studies. Whole genome screens using a linkage analysis approach can be used to 
identify chromosomal regions that are shared in excess by affected members within 
families. The basic principle of  this method is that loci that lie close together on a 
specific part of  the genome are likely to be transmitted together. In this way, affected 
relatives are likely to more often share markers in the close proximity of  a causal 
disease mutation than unaffected relatives. In the case of  an increased frequency of  
a certain marker, further screening of  the chromosomal region is required to identify 
the causative mutation. Candidate gene studies are based on association analyses, 
which can be conducted in population-based and family-based studies. In population-
based genetic association studies, the frequency of  allelic variants are compared 
between a group of  unrelated patients and a group of  healthy controls. In this case an 
association can be due to the biological consequences of  the marker studied (causative 
relationship) or to a gene that is in close proximity and inherited together with the 
marker (linkage disequilibrium). In a family-based association study, the difference 
between the frequency of  allelic variants transmitted from heterozygous parents to 
the affected offspring are compared with the frequency of  markers not transmitted 
(transmission-disequilibrium test). Population-based genetic association studies are 
presently the only way to unravel the contribution of  genetic factors in GBS, as no 
occurrence of  large families has been reported.
Single nucleotide polymorphisms
Single nucleotide polymorphisms (SNPs) in candidate genes are most commonly 
studied in population-based genetic association studies. These SNPs are widely 
distributed throughout the genome and are by definition present in at least 1% of  the 
general population.105 The distribution of  SNPs can be studied at allelic and genotypic 
level (Figure 2). Recently, the Human Genome Consortium reported a near complete 
sequence of  the human genome, which covers 99% of  the gene-rich portion of  the 
genome consisting of  3x109 basepairs.106 About 10x106 SNPs are expected to be 
distributed throughout the genome, as one SNP is approximately present per 300 base 
pairs. Within a protein-coding gene these SNPs can be located in (i) the promoter 
region, which is involved in the transcriptional regulation of  the gene expression, (ii) 
the coding region which is translated to a protein, (iii), the intron which is not translated 
to a protein but is involved in splicing, (iv) 3’ untranslated region (UTR) which affects 
the stability of  RNA. In this manner a SNP can account for differences in protein 
levels, altered function of  a protein or the absence of  a protein.107 An example is 
represented in Figure 3. In clinical terms SNPs can influence a person’s susceptibility 
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to develop GBS upon infection but can also cause differences in the severity of  
disease and outcome. Moreover, these SNPs can influence the way a patient responds 
to immunosuppressive therapy. Assessing the frequencies of  SNPs in genes expected 
to be involved in the aberrant immune response in GBS patients can provide useful 
information about the pathogenesis, susceptibility, progression, response to specific 
types of  treatment and outcome of  GBS. 
Figure 2. Single nucleotide polymorphism.
This figure represents an example of  a distribution of  the allele and genotype frequencies of  a single SNP, 
which is located in the CTLA4 gene (A(+49)G). When taking only one copy of  DNA (1 chromosome) 
into account the SNP locus is referred to as an allele. An individual, however, carries two alleles as they 
inherit one of  each parent. The combination of  two alleles is called a genotype. 
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Methodological considerations
As SNPs are abundantly present throughout the genome, a selection of  specific SNPs 
was made, which was primarily based on our current understanding of  the pathogenesis 
of  GBS and on SNPs in candidate genes reported in literature. The selected SNPs were 
located within protein-encoding genes and fulfilled the following criteria: (i) immune 
response genes suspected to play a role in the pathways that are likely to be involved 
in the pathogenesis of  GBS, (ii) assumed or proven to have a functional effect and (iii) 
reported to be associated with other autoimmune or infectious disorders. 
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Figure 3. Functional effect of a single nucleotide polymorphism. 
This figure represents an example of  a single nucleotide polymorphism (SNP) that is located within in the 
peptide leader sequence of  the human CTLA4 gene. At position +49 some individuals have a guanine 
(G) as nucleotide incorporated whereas others have an adenosine (A). This change results in an amino 
acid substitution: Ala (alanine) versus Thr (threonine) in codon 17 affecting the peptide leader sequence. 
The GG genotype is associated with a lower expression of  CTLA-4 and a higher proliferating T-cell 
response.114
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Since GBS is a rare and heterogeneous disorder, it is to be expected that many 
genes are involved. Therefore each individual gene will only have a small effect on 
susceptibility or outcome.108 To detect these small effects, which may only occur in 
subgroups, a large sample size of  patients described in detail with respect to infections, 
anti-ganglioside antibodies, clinical, features and outcome is required to perform 
subgroup analyses. Performing multiple comparisons, however, might result in false 
positive associations.109 It is still a matter of  debate whether or not to correct for 
multiple testing, as too conservative corrections might result in false negative studies. 
One way to reduce the risk of  false positive associations is to also study the functional 
effects of  the observed association within the study population and to confirm an 
association in another cohort of  GBS patients.
Outline of the thesis
Guillain-Barré syndrome is a heterogeneous post-infectious immune-mediated 
polyneuropathy in which pathogen-derived factors as well as host factors are likely 
to be involved in the pathogenesis. This thesis focuses on the contribution of  genetic 
host factors in Guillain-Barré syndrome. To accommodate for the heterogeneity of  
GBS, the putative role of  the SNPs was also studied in relation to defined clinical and 
immunological subgroups. 
The presence of  a familial form of  GBS or multiplex families would be of  great 
Table 3. Serological and clinical subgrouping of Guillain-Barré syndrome.
serological subgroups clinical subgroups   general characteristics
antecedent infection  severity based on MRC-sumscore*  age
C. jejuni severity based on F-score#  sex
Cytomegalovirus artificial respiration  
Epstein-Barr virus cranial nerve deficits  
M. pneumoniae sensory deficits  
 poor outcome (based on F-score 
 at 6 months)  
anti-ganglioside antibodies    
anti-GM1    
anti-GQ1b    
anti-GD1a    
anti-GM2
* Severely affected patients were defined as an MRC-sumscore < 40 and mildly affected patients as an 
MRC-sumscore ≥ 40. The MRC-sumscore ranges from 0 (tetraparalysis) to 60 (normal). # Severity of  
disease was based on the functional disability score (F-score) at nadir. Mildly affected patients are still 
capable of  walking independently, while severely affected patients are not able to walk independently 
and some need artificial respiration.
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advantage to unravel genetic susceptibility factors. Therefore, we actively searched 
for families with two or more affected family members. The results are described in 
Chapter 2.
Chapters 3-6 describe the results of  several population-based genetic association 
studies, in which we assessed whether SNPs in immune-regulatory genes confer 
susceptibility or are related to clinical or serological subgroups of  GBS. These studies 
were performed on a unique cohort of  about 275 Dutch GBS patients. More than 
half  of  the patients had participated in one of  the Dutch randomised controlled 
trials and are therefore documented in high detail with regard to antecedent infection, 
anti-ganglioside antibodies, severity of  disease, outcome and residual deficits, thereby 
enabling subgroup analysis (Table 3). As a control group, 212 healthy Caucasian blood 
bank donors, who were representative for the Dutch population based on their HLA-
typing, were used. 
Each chapter represents the results based on genes that are involved in different 
phases of  the immune response: pathogen-recognition (Chapter 3), antigen 
presentation and costimulation (Chapter 4), complement and macrophage mediated 
damage (Chapter 5) and apoptosis (Chapter 6). In Appendix 2 the complete list of  
SNPs studied is represented. 
Chapter 7 discusses the significance of  the results described in Chapters 2-6. 
Finally, directions for future investigations are put forward, mainly based on the results 
from the studies presented in this thesis. 
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Abstract
This report describes 12 Dutch families of  which at least two members have had 
Guillain-Barré syndrome (GBS). We observed an earlier onset of  GBS in successive 
generations. The occurrence of  GBS within families suggests a role for genetic factors 
in the pathogenesis of  GBS. 
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Introduction
Although Guillain-Barré syndrome (GBS) is the most common cause of  a flaccid 
paralysis in the Western world, it is still a rare disease. In the Netherlands, the incidence 
rate is 1.18 cases per 100.000 persons per year.1  It is not yet known why about 1 in 
1000 persons develops GBS after a Campylobacter jejuni infection.2 Genetic susceptibility 
and other host factors may play a role in the pathogenesis of  GBS. Although generally 
a sporadic disease, a few familial occurrences of  GBS have been reported (Table 1).3-9 
To examine the evidence for genetic susceptibility to develop GBS, we searched for 
families in the Netherlands in which at least two members have had GBS. Here we 
report the time and age at onset, antecedent clinical infections and other clinical 
characteristics of  the patients within these families.
Table 1. Overview of previously published familiy reports of Guillain Barré 
syndrome.
Family age at  relation time- prodromal illness clincial features
 diagnosis  interval
ref. 3 71 years brother  pain radiating from lumbar region  gradually increasing weakness
 73 years sister 4 years pain radiating from lumbar region  paraesthesia, weakness
ref. 4 56 years father  no comment low back pain, paralysis
 24 years daughter 2 years “nettle rash” paraesthesia
ref. 5 2 years brother  febrile illness and cold progressive weakness, 
     hyporeflexia, dysphagia, death
 22 months sister 4 years pharyngitis weakness, ataxic gait
 9 months brother 7 years fever and rinorrhea tetraparalysis, ventilated
ref. 6 58 years father  flu-like weakness, paresthesia, bilateral 
     facial palsy, ventilated
 43 years son 9 years URTI weakness, paresthesia
ref. 7 50 years father  haemoroidectomy followed 1 year later weakness and sensory
     loss, by right hand weakness
     AIDP
 24 years daughter 4 years EBV lower limb weakness, AIDP
ref. 8 19 mnths sister  Diarrhea (C. jejuni) pure motore, dysphagia,nuchal
     weakness, opthalmoplegia
 3 1/2 years sister 10 days Diarrhea (C. jejuni) pure motore, dysarthria, 
     opthalmoplegia, ventilated
ref. 9 35 years mother  headache and retro-orbital pain weakness and sensory deficits, 
     bilateral facial palsy, 
     dysarthria 
  6 years son 7 years general anaesthetic, sore throat lethargy, neck pain and bulbar
     weakness
All selected family cases are reported as Guillain-Barré syndrome and written in English. Insufficient information is 
available whether all cases meet the diagnostic criteria for GBS. Most of  the patients had increased CSF protein and 
loss of  deep tendon reflexes, which are not listed in the table. C. jejuni: Campylobacter jejuni, EBV: Epstein-Barr virus, 
AIDP: acute inflammatory demyelinating polyneuropathy.
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Methods
Study population
In this study we included families in which at least two members were diagnosed as 
GBS. To identify as many families with GBS patients as possible, we obtained patients 
in three ways:
1.  One group of  patients had already participated in one of  the Dutch trials or 
surveys. In 2001-2002 the patients were asked to participate in a genetic population-
association study. Those who agreed to take part were visited and asked to fill in a 
questionnaire, including the question whether or not they had affected relatives.
2.  In 2003, the Dutch Society of  Muscle Disorders (VSN) sent all of  their 298 present 
members with GBS or chronic inflammatory demyelinating polyneuropathy 
(CIDP) a letter to inform them about the project and asked them whether they had 
a relative with GBS or CIDP. 
3.  In the period 2002-2003, GBS patients admitted to the Erasmus Medical Center 
were asked about any affected relatives. 
Families were only included when the probands as well as their affected family members 
fulfilled the diagnostic criteria for GBS.10 Parental consent was sought when patients 
were younger than 18 years old. Clinical characteristics of  the patients were obtained 
from a letter of  discharge or a standardized questionnaire. The protocol for this study 
was reviewed and approved by the Medical Ethical Committee of  Erasmus Medical 
Center and all patients who participated gave their written informed consent.
Statistical approach
The standardized morbidity ratio was used to verify whether the incidence of  GBS 
among siblings was higher than expected based on the general population data. The 
SMR was estimated using the data from the genetic population-association study. 
Results
In total we managed to contact approximately 500 GBS patients. Within this group of  
patients, 20 families were initially contacted, but patients in two families suffered from 
a subacute GBS or CIDP, in two other families the diagnosis of  one of  the patients 
could not be verified and in four other families at least one of  the patients refused 
participation. Finally, 12 families were included in this study of  which the pedigrees 
and the age of  onset of  the affected members are shown in figure 1. Eleven women 
and 14 men were affected within these families. 
Among siblings, the observed incidence was 2.6 fold increased compared to the 
expected incidence (SMR 2.6, 95% C.I. 0.4-18.5, P=0.32). With regard to the age of  
onset, we observed a trend over generations in a way that the age of  onset decreased 
in younger generations. The median difference in age at onset between siblings was 
6 years (ranging from 0 to 14 years) and between cousins 6.5 years (ranging from 
1 to 17 years). The difference in age between two mothers and their sons was in 
both cases 33 year. The median difference in age between aunts or uncles and their 
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nieces or nephews was 27 years (ranging 26 from to 49). The age difference between 
grandmother and her grandson was 47 years. The year of  diagnosis and the clinical 
characteristics are summarized in table 2. The median time-interval between the years 
of  onset of  GBS in affected relatives is 6.5 years (ranging from 2 months to 22 years). 
The prodromal illness, clinical features and severity of  the disease varied between the 
affected members within the families. Since the estimated recurrence rate of  GBS 
seems about 1-5%, it is of  note that one of  the familial patients had four times an 
episode of  GBS (Family 8).
Discussion
In this study we describe 12 families in which at least two members had GBS.  Until 
now, worldwide only 7 families with two or three probands have been reported (see 
table 1).3-9  These reports described families in which siblings (n=3) or parents and 
their children were affected (n=4). In our report we further described families in 
which second and third degrees relatives are affected. 
In our study, which is not an epidemiological survey, the number of  reported 
families is insufficient to prove that there is a familial occurrence of  GBS. The slightly 
more frequent occurrence of  GBS within siblings, the observed earlier onset of  GBS 
in successive generations and the patient having four times GBS might suggest a 
genetic susceptibility. However, more patients are needed to obtain a precise estimate 
of  the SMR and to confirm the trend of  a decrease in age at onset over generations. 
Retrospectively, this trend can also be observed in previously reported family-studies: 
the median difference in age of  onset between affected parents and their child was 
27.5 years and between siblings 1.25 years.3-9 The earlier onset in successive generations 
could also merely reflect the lack of  follow-up time, since the youngest generation has 
not lived long enough to be ascertained at later age. 
Environmental factors like antecedent infections play an important role in the 
pathogenesis. In some of  the families GBS was preceded by the same type of  
antecedent infection, while in other families and even in the patient who had four 
episodes of  GBS, the prodromal illnesses were different. The observed large time-
interval between the onsets of  symptoms within the families excluded the possibility 
that GBS was triggered within the same period of  antecedent infection. Besides the 
clinical symptoms related to a specific pathogen, no specific clinical variants within 
families are observed, which is in line with the other case-reports.3-9
This paper supports that GBS is rather a complex genetic disorder than a 
Mendelian inherited disorder, which outcome is determined by environmental and 
genetic factors. Investigation of  the genealogy and molecular genetics of  a large 
number of  families with GBS may give more insight into host factors determining a 
subject’s susceptibility to GBS. 
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Table 2.  Clinical characteristics of familial Guillain-Barré reports.
Family Relation year at  prodromal illness Clinical features F-score at 
  onset                                                nadir*
1.  Brother 1986 flu SM, bilateral facial palsy 4
 Cousin 1989 fatigue, fever (CMV) SM 3 
 Sister 2002 sinusitis  SM 1
2. Son 1994 URTI SM, bulbar weakness 3
 Mother 1999 diarrea, sore throat M 4
3. Grandmother 1975 flu SM, ataxia 2
 Grandson 1997 none M, pain 3
4. Sister 2003 flu-like Bulbar weakness, ataxia 2 
 Brother 2003 URTI SM, ataxia 2
5.  Cousin 1989 sore throat M  4
 Cousin 2002 flu SM, dysphagia, ptosis 4
6. Sister 1988 diarrhea M, bilateral facial palsy,  5
    bulbar weakness  
 Brother 1996 diarrhea  M 1
7. Mother 1996 pregnant (CMV) SM, bilateral facial palsy 5
 Son 1996 none (CMV) SM 5
8. Nephew 1996 flu M, bilateral nVII palsy 2
 Aunt 1999 URTI M, opthalmoplegia 2  
  1999 diarrhea M, ptosis 2 
  2000 sore throat M, opthalmoplegia 4
  2004 sore throat M, opthalmoplegia 3
9. Niece 1985 none SM 4
 Uncle 1995 diarrhea (C. jejuni) SM 5
10. Cousin 1999 diarrhea SM, bilateral facial palsy 3
 Cousin 2001 diarrhea (C. jejuni) M, bulbar weakness, 
    autonomic dysfunction 5
11. Uncle 1996 flu SM, pain 4
 Niece 1998 diarrhea M, pain 4
12. Brother  1990 Diarrhea  M, facial palsy 5
 Sister 2004 None (C. jejuni) M 3
*GBS disability score at nadir: 1= minor symptoms and capable of  running, 2= able to walk 10m across 
an open space without assistence, 3= able to walk 10m with a walker or support, 4= bed or chairbound 
and unable to walk as in 3, 5= assisted ventilation required for at least part of  the day or night. 
SM: motor and sensory deficits, CMV: cytomegalovirus, URTI: upper respiratory tract infection, M: pure 
motor variant, C. jejuni: Campylobacter jejuni.
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Abstract
Guillain-Barré syndrome (GBS) is an acute immune-mediated polyneuropathy 
preceded by infections. Campylobacter jejuni is the most frequent pathogen and its 
lipopolysaccharide (LPS) induces antibodies cross-reactive with gangliosides. In this 
study we assessed whether known functional polymorphisms in the LPS receptors 
CD14 and Toll-like receptor 4 (TLR4) are associated with an increased susceptibility 
for GBS or with C. jejuni serology or C. jejuni related clinical and serological features. 
Comparison of  the genotypes of  242 GBS patients and 210 healthy subjects showed 
that polymorphisms in CD14 and TLR4 did not confer disease susceptibility and were 
not associated with C. jejuni infection.  
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Introduction
Guillain-Barré syndrome (GBS) is an acute heterogeneous immune-mediated 
polyneuropathy, which is frequently preceded by an infection. Campylobacter jejuni, 
a Gram-negative bacterium of  which LPS is the major component of  the outer 
membrane, is the most commonly found pathogen in the Netherlands.1 The currently 
favoured hypothesis on the immunopathogenesis of  GBS indicates that molecular 
mimicry between C. jejuni LPS and gangliosides expressed on peripheral nerves leads 
to the production of  pathogenic cross-reactive antibodies. This concept is supported 
by the observed association between antecedent C. jejuni infections and the presence 
of  antibodies to GM1, GM1b, GD1a, GalNAc-GD1a and GQ1b, cross-reactivity 
of  anti-LPS antibodies to these gangliosides, and molecular mimicry between LPS 
and gangliosides. Finally, the concept is supported by the induction of  cross-reactive 
antibodies in animals after LPS immunization.2-6 The fact that such a cross-reactive 
immune response to LPS and gangliosides is rare after a C. jejuni infection in humans, 
may explain why only 1:1000 persons develop GBS after a C. jejuni enteritis.7 This 
would indicate that host factors determining the immune response to LPS play a 
crucial role in the etiology of  GBS.
CD14 and Toll-like receptor 4 (TLR4) are important in the antigen presentation 
and intracellular signalling of  LPS. CD14 is a 55kDa glycoprotein, which is mainly 
expressed on mature monocytes, macrophages and activated granulocytes.8 Recently, 
a functional polymorphism in the promoter region of  the CD14 gene has been 
described. This C (-260) T polymorphism is located at one of  the binding sites for 
the Specificity protein (Sp) transcription factors, which are involved in regulation of  
the CD14 transcription and level of  expression. The T-allele is associated with higher 
expression of  CD14 on peripheral blood mononuclear cells, particularly in the case 
of  TT homozygotes. Moreover, this T-allele is associated with Crohn’s disease and an 
increased risk of  a myocardial infarct after a Gram-negative infection.9-12
Since CD14 lacks a transmembrane domain, TLR4 is required for intracellular 
signalling. After CD14 has transferred LPS to the TLR4 complex, a cascade of  
intracellular events leads to the activation of  NF-κB, which in turn induces the 
transcription of  several cytokine genes such as IL-1, IL-6 and TNF-α resulting 
in a pro-inflammatory environment.13, 14 In the TLR4 gene, two co-segregating 
polymorphisms in the fourth exon have been reported: A(+896)G and C(+1196)T. 
Both polymorphisms result in an amino acid substitution and are usually referred to 
as Asp299Gly and Thr399Ile, which alter the structure of  the extracellular domain of  
TLR4. The mutant allele of  the Asp299Gly in the fourth exon of  TLR4 is associated 
with an attenuated immune response to LPS and secretion of  lower levels of  pro-
inflammatory cytokines.15, 16 Individuals having the Asp299Gly TLR4 allele have 
an increased risk of  Gram-negative infections, Gram-negative shock and systemic 
inflammatory response syndrome.17-19
Recent advances in the field of  TLR-signaling have established their importance 
for the initiation of  both innate and adaptive immune responses and their requirement 
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for maintaining immune tolerance.20 Ligation of  TLR on dendritic cells (DC) initiates 
a process of  cell maturation and upregulation of  the expression of  MHC and 
co-stimulatory molecules like B7 and of  the secretion of  various cytokines and 
chemokines. In case of  GBS the induction of  cross-reactive antibodies to LPS and 
gangliosides may be caused by inappropriate activiation of  the DCs via the CD14-
TLR4 complex. Therefore, we hypothesized that C. jejuni infected GBS patients have 
an altered immune response to LPS due to polymorphisms in these LPS-signalling 
genes which affects the secretion of  pro-inflammatory cytokines and influences the 
adaptive immune response. We investigated whether these polymorphisms occur more 
often in GBS patients and whether these single nucleotide polymorphisms (SNPs) are 
related to C. jejuni infection, anti-ganglioside antibodies and clinical subgroups.
Material and Methods
Study population
Peripheral blood samples were collected from 242 Caucasian GBS patients (median 
age at onset of  disease 45 years, range 7-82 years, male/female ratio=1.03) who had 
participated in trials or other national survey studies coordinated by the Department 
of  Neurology of  Erasmus MC. All patients fulfilled the diagnostic criteria for GBS.21 
The protocol of  this study was reviewed and approved by the Medical Ethical 
Committee of  Erasmus MC, and all patients gave their written informed consent. 
Of  these 242 patients, 137 had participated in one of  the Dutch GBS trials and are 
therefore prospectively documented in high detail with regard to clinical and serological 
aspects of  the disease.22, 23 The patients enrolled in one of  these trials were followed 
for six months after randomisation. At randomisation these patients were examined 
clinically and blood was drawn for serological screening for antibodies against the 
most common antecedent infections in GBS (C. jejuni, cytomegalovirus, Epstein-Barr 
virus and Mycoplasma pneumoniae), and for the presence of  anti-ganglioside antibodies 
according to standard procedures.1, 24 During follow-up, the patients were neurologically 
examined at 16 time points according to the protocol. The Medical Research Council 
(MRC)-sumscore25, the GBS functional disability score26, the involvement of  sensory 
and cranial nerves were established at all these time-points. The severity of  the disease 
was defined in two different ways. One was based on the MRC-sumscore (ranging 
from 0-60) at nadir; mildly affected patients were defined by an MRC-sumscore ≥ 40 
and severely affected patients by an MRC-sumscore < 40.27 The other was based on 
the GBS functional disability score at nadir: mild disease was defined as able to walk 
independently (F-score of  1 or 2) and severe disease as unable to walk independently 
(F-score of  3, 4 or 5).28 Additionally, clinical and serological information was obtained 
from 35 patients who had participated in a prospective study: anti-ganglioside 
antibodies were determined in 28 of  the patients, C. jejuni serology in 24 patients and 
F-score at nadir in 34 patients.29 In the remaining 70 patients, additional information 
was only available on sex and age.
Genomic DNA of  210 Caucasian healthy subjects (median age 35 years, range 19-60 
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years, male/female-ratio=0.65) was provided by the Laboratory for Histocompatibility 
and Immunogenetics, Sanquin Bloodbank South West Region, The Netherlands. 
These controls were not serologically screened for the presence of  antibodies to 
Campylobacter jejuni. All healthy subjects had given written informed consent. 
Isolation of genomic DNA
Isolation of  genomic DNA from EDTA anti-coagulated peripheral blood samples was 
performed with the use of  the Invisorb® MaxiBlood kit (Invitek, Berlin, Germany) 
according to the manufacturer’s instruction. At the end of  the isolation procedure, the 
DNA samples were dissolved in 0.1 TE-buffer (1 mM Tris-HCl (pH 7.5) + 0.1 mM 
EDTA) and stored at -80°C. DNA samples for SNP detection were diluted in milli-Q 
water to a final concentration of  10 ng/µl and stored at –20°C.
RFLP analysis of the C(-260)T polymorphism in the promoter 
region of  CD14
Amplification of  a 367-bp fragment of  the CD14 promoter was performed using the 
Perkin Elmer DNA Thermal cycler. The polymerase chain reaction (PCR) was run 
in a 50 µl volume containing 200 ng of  genomic DNA, 12.5 pmol of  each primer 
(Table 1), dNTPs at 0.1 mM and 0.2 U of  Ampli Taq DNA polymerase (Perkin 
Elmer, Norwalk, CT) and 1x Ampli Taq Gold Gene Amp 10x PCR Buffer II & 
MgCl2 (Perkin Elmer) and milliQ-water. The PCR profile included 1 cycle of  7 min 
at 95°C; 40 cycles of  45 sec at 92°C, 90 sec at 60°C and 2 min at 72°C; 10 min at 
72°C and 10 min at 4°C. The PCR products were analysed by restriction fragment 
length polymorphism (RFLP) analysis. Five µl of  PCR product and 5 µl of  an internal 
control were digested in 2 units of  restriction endonuclease HaeIII (Roche Diagnostics, 
Mannheim, Germany) at 37°C for two h. Digests were analysed by 6% acrylamide gels 
+ 0.5X TBE (45mmol/l Tris, 45 mmol/l boric acid, 1.25 mmol/l EDTA). The gels 
were stained with ethidium bromide and DNA was visualized with UV light. In every 
lane, the internal control was digested into a 479-bp and 97-bp fragment.  Digestion 
of  the samples yielded bands of  367 bp in TT homozygotes, 155-bp and 212-bp in CC 
homozygotes and all three restriction bands in heterozygotes.
LightCycler analysis of the Asp299Gly and Thr399Ile 
polymorphisms in the TLR4 gene
In this study we detected the Asp299Gly and Thr399Ile polymorphism of  the human 
TLR4 gene in a single LightCycler assay with one set of  primers and two sets of  
hybridisation probes (Table 1). The general principle of  this PCR-based method have 
been previously described.30 Primers and hybridisation probes for detection of  the 
SNPs were designed by TibMol Biol (Mannheim, Germany). The PCR-reaction and 
the melting curve were performed in LightCycler capillaries (Roche Diagnostics) with 
a final volume of  20 µl, containing 10 ng genomic DNA, 0.5 µM of  each primer, 
0.15 µM of  each hybridisation probe, 1x LightCycler DNA Master Hybridisation 
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Probes (Roche Molecular Biochemicals, Mannheim, Germany) and 3 mM MgCl
2
. 
Sealed capillaries were centrifuged and placed in the rotor of  the LightCycler 
instrument (Roche Diagnostics). The PCR thermocycling profile included 10 min 
at 95°C, followed by 45 cycles of  95°C for 0.1 sec, 56°C for 15 sec and 72°C for 20 
sec. Next, the melting curve profile was performed, which included 1 cycle of  95°C 
for 0.1 sec, 40°C for 1 min after which the temperature was slowly increased (0.1°C/
sec) to 85°C under continuous detection of  the emitted light. Finally, the cooling 
down was performed at 40°C for 30 sec. Due to the fact that in this experiment two 
differently labelled fluorophores were used, interference between the channels could 
occur. To compensate for this, an installed colour compensation set was used (Roche 
Molecular Biochemicals). Data were analysed using the melting curve program. In 
each experiment we used sequenced DNA from confirmed control donors for each 
genotype.
Statistical analysis 
Verification of  Hardy-Weinberg equilibrium was performed using the statistical 
method program of  Ott. The genotype and allele-frequencies between patients and 
healthy subjects and between subgroups of  patients were compared using Pearson’s 
chi-square test. When one of  the cells had an expected value less than five, the Fisher’s 
exact test was used. Allelic odds ratios and confidence intervals were computed. 
P- values less than 0.05 were considered to be significant.
Results 
Clinical and serological characteristics of the GBS patients
With regard to the clinical characteristics, 17.5% of  the patients had a pure motor 
variant of  GBS, 19% needed artificial respiration, 47.8% were severely impaired 
based on the MRC-sumscore (MRC-sumscore <40 out of  60) at nadir and 94.7% 
had a severe disease course based on the GBS functional disability score at nadir 
(F-score> 3). In the weeks prior to GBS, 28.1% of  the patients had diarrhoea and 
27.2% had a serologically confirmed C. jejuni infection. Anti-GM1 antibodies were 
present in 25.5% of  the patients and anti-GQ1b antibodies in 12.7%. These clinical 
characteristics and the presence of  anti-GM1 and anti-GQ1b antibodies are related 
to a C. jejuni positive serology and were present in a similar percentage of  patients as 
reported in former publications. Furthermore, associations between a C. jejuni positive 
serology and anti-GM1 (p=0.001) and anti-GQ1b antibodies (p=0.02) were very 
similar to those described previously.24  
No association between SNPs in LPS-signalling genes and Guillain-
Barré syndrome
To determine whether CD14 and TLR4 polymorphisms confer susceptibility in GBS 
patients, we assessed the genotypes in 242 GBS patients and 210 healthy subjects. The 
genotype distribution of  the C (-260) T polymorphism within the CD14 gene and the 
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Asp299Gly polymorphism in the TLR4 gene did not differ between GBS patients 
and controls (see Table 2). Moreover, these genotype distributions also did not differ 
between C. jejuni infected patients (n=41) and 110 GBS patients who did not have an 
antecedent C. jejuni infection (see Table 2). 
Since the TLR4 Thr399Ile mutation co-segregates with the TLR4 Asp299Gly 
mutation, the genotype distribution of  this polymorphism was almost identical to 
that found for Asp299Gly. Thr/Thr was present in 89.3% of  the GBS patients and 
in 86.2% of  the controls and Thr/Ile was present in 10.7% of  the GBS patients and 
13.3% of  the controls. In the control group one Ile/Ile homozygote was detected. A 
few exceptions with regard to the co-segregation of  the mutant alleles in the TLR4 
gene were noticed: in one patient and one control a Gly-allele was inherited with a 
Thr-allele and in one other patient an Asp-allele with an Ile-allele. 
As the SNPs were in Hardy-Weinberg-equilibrium, the allele frequencies of  the 
SNPs in CD14 and TLR4 could be compared between patients and controls. The 
T-allele of  the SNP in CD14 was present in 51.4% of  the patients and in 53.8% of  the 
controls and this difference was not significant (p=0.5, OR=0.9, 95% C.I. 0.7 to 1.1). 
The distribution of  the Gly-allele did not differ between patients and controls (5.4 vs. 
7.4%; p=0.2, OR=0.7, 95% C.I. 0.4 to 1.2).
Table 2. Genotype distribution of SNPs in CD14 and TLR4 in controls and GBS 
patients.
  controls GBS-patients  GBS-patients
   C. jejuni positive serology   C. jejuni negative serology
  n=210 % n=242 % n=41 % n=110 %
CD14           
C(-260) T           
CC 50 23.8 58 24.0 7 17.1 25 22.7
CT 94 44.8 119 49.2 23 56.1 52 47.3
TT 66 31.4 65 26.8 11 26.8 33 30.0
         
TLR4         
Asp299Gly         
Asp/Asp 180 85.7 216 89.3 38 92.7 97 88.2
Asp/Gly 29 13.7 26 10.7 3 7.3 13 11.8
Gly/Gly 1 0.5 0 0.0 0 0.0 0 0.0
The genotype distributions were compared between the GBS patients and controls by using the Pearson 
chi-square test. No significant differences for the SNPs in CD14 and TLR4 were found. Furthermore, no 
significant association between these SNPs and C. jejuni serology was observed. TLR4: Toll-like receptor 
4.
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No association between SNPs in the LPS-signalling genes and 
C. jejuni serology and related anti-ganglioside antibodies, 
neuroligcal deficits and prognosis
To test our hypothesis that SNPs in CD14 and TLR4 are involved in the altered 
immune response in C. jejuni infected GBS patients, we subdivided the patients into 
different groups according to clinical and serological characteristics of  a C. jejuni 
infection. Since a pure motor variant of  GBS, a severe course of  disease, anti-GM1 
and anti-GQ1b antibodies are more frequently present in the C. jejuni infected group 
of  patients, we determined the association between these characteristics and the SNPs. 
The occurrence of  any of  the C. jejuni related characteristics was not associated with 
one or more of  these SNPs (Table 3). Furthermore, we investigated whether there 
was an association between the SNPs and the severity of  the disease at different time-
points during follow-up. No relation between the severity, defined by MRC-sumscore 
or F-score, was found at randomisation, after four weeks or six months of  follow-up. 
Discussion 
We postulated that the aberrant immune response to LPS in GBS patients, 
characterised by the production of  high titers of  cross-reactive anti-ganglioside 
antibodies was related to polymorphisms in the CD14 and TLR4 genes. In this study 
we have shown that in a large group of  GBS patients, representative for the whole 
spectrum of  GBS, the SNPs in CD14 and TLR4 were not related to the susceptibility 
to develop GBS. Furthermore, we showed that these SNPs were not related to C. jejuni 
serology, neurological deficits and anti-ganglioside antibodies associated with C. jejuni 
infection.
The SNPs we have studied have previously been shown to be functionally relevant 
and to be associated with disorders in which Gram-negative infections play a role.9-12 
As far as we know, no other functional polymorphisms in the CD14 and TLR4 genes 
have been reported in the literature. We detected the SNP in CD14 with RFLP-
analysis. In all experiments, an internal control was used to verify whether there had 
been a total enzymatic digestion. The SNPs in the TLR4 gene were detected by using 
the LightCycler technique, which is highly sensitive and specific. The samples we 
sequenced were in accordance with the LightCycler results. Three sequenced samples 
with different genotypes were used in the experiments as an internal control. With 
both techniques, the genotypes of  all samples could be determined. The genotype 
distributions of  the CD14 and TLR4 polymorphisms in our large group of  Caucasian 
controls were comparable with those found by others, suggesting that the control 
group and the technique we have used are representative. 
The most frequent antecedent event related to GBS is a C. jejuni infection, which 
occurs in about 30% of  the patients. This infection is very common in the general 
population of  which most of  the individuals suffer minor complaints and only less 
than 1:1000 subsequently develop GBS. To be able to accept or reject the hypothesis 
that the SNPs in CD14 and TLR4 do confer susceptibility of  GBS after a C. jejuni 
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infection, it could be argued that C. jejuni enteritis patients who did not develop GBS 
should optimally have been used as control group. Based on the high incidence of  
C. jejuni infection, the majority of  controls are expected to have had an infection at any 
point in life. However, we cannot exclude the possibility that some of  the controls will 
develop GBS after a C. jejuni enteritis in the future. Although the controls were younger 
in age than the GBS patients, we want to stress that when considering different age 
strata the genotype and allele frequency in cases and controls did not vary over these 
strata. Based on our study, allelic ORs higher than 1.2 were rejected for both SNPs. 
We also tested our hypothesis in another way.  We therefore subdivided the patients 
into two groups based on C. jejuni serology, the ones with a positive C. jejuni serology 
and the ones with a negative serology. Additionally, we have taken into account the 
clinical symptoms that are related with a C. jejuni infection within the GBS patients. The 
C. jejuni related symptoms, such as diarrhoea, severity, pure motor variant and presence 
of  anti-ganglioside antibodies also showed no association with the determined SNPs.
Given the central role of  antecedent C. jejuni infections and cross-reactive immune 
response to C. jejuni LPS in GBS, other LPS receptors than CD14 and TLR4 may 
be involved. There is evidence that CD14 and TLR4 are part of  a larger antigen 
recognition and signalling complex. In the initial step LPS is bound to CD14, which 
in turn catalyzes the transfer of  LPS to a complex of  receptors, including chemokine 
receptor 4 (CRCX4), heat shock protein (Hsp) 70 and 90, and growth differentiation-
factor 5 (GDF5). The TLR4-MD-2 complex is subsequently recruited to achieve 
maximum responses upon LPS stimulation.31, 32  Besides the membrane-bound 
receptors, molecules involved in the intracellular signalling pathway of  TLR4 may 
also be involved.33 Recently, two different mutations within the IRAK4 gene have 
been reported in patients with pyogenic bacterial infections and an impaired response 
to LPS.34 Moreover, B cells do express another TLR molecule, RP105, which co-
regulates the humoral immune response to LPS. Polymorphisms in all the genes of  
above-mentioned molecules may be involved in conferring susceptibility to GBS after 
an infection with C. jejuni. Until now polymorphisms in the IgG-Fc receptor genes, 
immunoglobulin KM gene and IL-10 gene have been reported to be associated with 
disease susceptibility or severity of  GBS.35-38
In this study we have shown that SNPs in CD14 and TLR4 neither conferred 
susceptibility to develop GBS nor were related to C. jejuni serology, anti-ganglioside 
antibodies or neurological deficits related to a C. jejuni infection. Since GBS is a 
heterogeneous disorder of  multifactorial origin other SNPs are most likely involved 
in conferring susceptibility and severity of  the disease. With regard to the C. jejuni 
infected GBS patients, SNPs in genes of  other molecules involved in LPS responses 
may be involved in conferring the susceptibility and clinical pattern of  GBS.
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Abstract
Objective: To assess whether human leucocyte antigen (HLA)-DRB1 and HLA-
DQB1 alleles confer susceptibility to Guillain-Barré syndrome (GBS) or are related to 
specific clinical or serological subgroups of  GBS.
Methods: The HLA-DRB1 and -DQB1 loci were genotyped by PCR amplification 
with sequence-specific primers in 164 well-documented Dutch patients with GBS and 
207 healthy Dutch control subjects. Patients with GBS were divided into subgroups 
based on clinical features, severity of  disease, antecedent infection, and anti-ganglioside 
antibodies. Data were compared with those of  all case-control HLA studies in GBS 
performed previously.
Results: In this case-control study, HLA-DRB1 and HLA-DQB1 alleles did not 
differ between GBS patients and control subjects. The frequency of  HLA-DRB1*01 
was significantly increased in patients who needed mechanical ventilation (OR 4.2, 
95% CI 1.9-9.6; p
c
=0.02). Multivariate logistic regression analysis showed that this 
association was independent of  the severity of  paresis and the presence of  cranial 
nerve involvement (p-values <0.05). There was a tendency towards an association 
between certain HLA alleles and several anti-ganglioside antibodies.
Conclusion: Human leucocyte antigen (HLA) class II antigens are not a general 
susceptibility factor in Guillain-Barré syndrome (GBS). However, HLA-class II alleles 
may be a determinant in distinct subgroups of  Guillain-Barré syndrome, indicating the 
need for further exploration in large-scale studies.
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Introduction
Patients with Guillain-Barré syndrome (GBS) show considerable variation in the 
pattern and severity of  neurological deficits, prognosis, type of  antecedent infection, 
and the presence of  anti-ganglioside antibodies. These antibodies are most likely 
evoked by molecular mimicry between microbial structures and gangliosides present 
on the peripheral nerves.1 However, this transient humoral autoimmune response, only 
rarely occurs in response to common types of  infections. The susceptibility to develop 
such an immune response as well as the clinical heterogeneity of  GBS may at least 
partially be explained by immune modulating genetic host factors.
The highly polymorphic human leucocyte antigen (HLA) system is one of  the 
prominent candidate gene clusters influencing GBS as it plays a central role in the 
immune responses to infection. Until now, inconsistent findings have been reported 
with regard to HLA-class II alleles as a susceptibility factor for GBS or its clinical 
and serological subgroups (Table 1; see also table E-1 on the Neurology Web site at 
www.neurology.org). The susceptibility to several autoimmune diseases is most closely 
linked with the class II HLA-DR and DQ-antigens.2 Therefore, we assessed whether 
HLA-DRB1 and HLA-DQB1 alleles confer susceptibility to GBS or are related to 
specific clinical and serological subgroups in the largest group of  well-documented 
GBS patients reported thus far (n=164). Furthermore, we compared our findings with 
previously published case-control studies.
Materials & Methods
Study population
One hundred and sixty-four Dutch Caucasian GBS patients, who had participated in 
one of  the Dutch treatment trials or other national survey studies, were enrolled in this 
study.3-5 All patients fulfilled the diagnostic criteria for GBS.6 Clinical manifestations, 
infections and ganglioside serology were documented in detail.4, 7, 8 Screening for 
antibodies against the most common antecedent infections in GBS (Campylobacter 
jejuni, Cytomegalovirus (CMV), Epstein-Barr virus (EBV) and Mycoplasma pneumoniae), 
and for the presence of  the most common anti-ganglioside antibodies were performed 
according to standard procedures.7,9 During follow-up, the patients enrolled in the 
treatment trials were neurologically examined at 13 to 17 different time points (ranging 
from day of  entry to six months of  follow-up). The Medical Research Council (MRC)-
sumscore of  6 bilateral muscle groups, ranging from 60 (normal) to 0 (tetraparalysis)10, 
the GBS functional disability score11 and the involvement of  sensory and cranial nerves 
were also established at these time points. The severity of  the disease was defined in 
two different ways according to previously reported criteria.8, 12 One was based on the 
MRC-sumscore at nadir. The median value of  this sumscore at nadir was used as a 
predefined cut-off  point; mildly affected patients were defined by an MRC-sumscore 
≥ 40 and severely affected patients by an MRC-sumscore < 40.8  The other was based 
on the GBS functional disability score (F-score) at nadir: mild disease was predefined 
as the ability to walk independently (F-score of  1 or 2) and severe disease as unable to 
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walk independently (F-score of  3, 4 or 5).12 The electrophysiological data of  the GBS 
patients were classified as acute inflammatory demyelinating polyneuropathy (AIDP), 
acute motor axonal neuropathy (AMAN), equivocal, normal or inexcitable according 
to previously described electrophysiological criteria.13
Two hundred and seven Dutch Caucasian healthy blood donors were used as 
controls. These control subjects were not age or sex matched. The protocol of  this 
study was reviewed and approved by the Medical Ethical Committee of  Erasmus MC, 
and all patients and healthy control subjects gave their written informed consent.
HLA-DRB1 and –DQB1 typing
Genomic DNA was extracted from ethylenediaminetetraacetate-anti-coagulated 
peripheral blood samples by a salting out procedure, which was performed with 
the use of  the Invisorb® MaxiBlood kit (Invitek, Berlin, Germany) according to the 
manufacturer’s instruction. Subsequently, HLA-DRB1and HLA-DQB1 typing was 
performed at the two-digit level by PCR–amplification with sequence-specific primers 
(PCR-SSP).14 
Literature search
To compare our data with previously published case-control studies in GBS, we 
performed a literature search in the Medline database (National Library of  Medicine, 
Bethesda, MD) using the keywords ‘Guillain-Barré’ and ‘HLA’. Publications written in 
English up to March 2004 were taken into account and all publications reporting case-
control studies were analyzed. The reference list of  these publications was screened 
for additional case-control studies.
Statistical analysis
The HLA-antigen frequencies of  GBS patients and control subjects and between 
different subgroups of  GBS patients were compared using the Fisher’s exact test 
(uncorrected p-values (p
u 
)). To adjust for the number of  alleles tested, we also 
calculated the corrected p-values (p
c 
). The strength of  the association was estimated 
by calculating the odds ratio’s using Woolf-Haldane’s method. Multivariate logistic 
regression was used to further analyze the observed associations. The level of  
significance was set at p
(c)
 < 0.05.
Results
Characteristics of GBS patients and controls
In this study, 77 women and 87 men were included as GBS patients with a median age at 
onset of  47 years (ranging from 7 to 82 years). Twenty-seven percent of  these patients 
had a gastro-enteritis as prodromal illness, while 39% had an upper-respiratory tract 
infection. C. jejuni serology was positive in 26%, CMV serology in 17%, EBV serology 
in 15% and M. Pneumoniae serology in 7% of  the patients. Anti-GM1 antibodies were 
detected in 23%, anti-GQ1b antibodies in 14% and anti-GM2 antibodies in 9% of  the 
patients. Furthermore, in this group of  patients the associations between a C. jejuni 
positive serology and anti-GM1 (p=0.001) and anti-GQ1b antibodies (p=0.02) were 
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very similar to those described previously.9 Mechanical ventilation was required in 21% 
and cranial nerve involvement was present in 56% of  the patients. A severe form of  
disease, based on the MRC-sumscore at nadir, was found in 49% of  the patients. Since 
an F-score ≥ 3 was an inclusion criterion for enrollment in the Dutch treatment trials, 
almost all of  the patients (96%) were classified as having a severe form of  GBS based 
on this score. The electrophysiological data were classified as AIDP in 67 patients 
(54%), AMAN in 4 patients (3%), equivocal in 51 patients (41%), inexcitable in 1 
patient (1%), and normal in 1 patient (1%).
The control group consisted of  125 Dutch women and 82 men with a median age 
of  35 years (ranging from 19 to 60 years). 
HLA-DRB1 and DQB1 allele distribution in GBS patients and 
controls
The HLA frequencies of  the healthy control subjects were compared with the 
serologically typed HLA frequencies of  a large cohort of  healthy Dutch controls 
(n=2440) and proved to be representative for the general Dutch Caucasian 
population.15 There was no significant difference in the frequencies of  HLA antigens 
between GBS patients and controls (Table 2).
Table 2. HLA class II allele distribution in Guillain-Barré patients and healthy controls.
 GBS patients (n=164)  controls (n=207)  OR (95% CI)
 n (%)  n (%)   
DRB1*01 35  (21)   41  (20) 1.1 (0.7-1.8)
DRB1*03 38  (23)   63  (30) 0.7 (0.4-1.1)
DRB1*04 56  (34)   58  (28) 1.3 (0.9-2.1)
DRB1*07 33  (20)   42  (20) 1.0 (0.6-1.6)
DRB1*08 11   (7)   11   (5) 1.3 (0.6-3.0)
DRB1*09   6   (4)    5   (2) 1.5 (0.5-4.8)
DRB1*10   4   (2)    7   (3) 0.8 (0.2-2.5)
DRB1*11 20  (12)   35  (17) 0.7 (0.4-1.2)
DRB1*12   6    (4)     3    (1) 2.4 (0.6-8.9)
DRB1*13 42  (26)   46  (22) 1.2 (0.7-1.9)
DRB1*14 18  (11)     9    (4) 2.6 (1.2-5.9)
DRB1*15 38  (23)   64  (31) 0.7 (0.4-1.1)
DRB1*16  2    (1)     7    (3) 0.4 (0.1-1.7)
DQB1*02 55  (34)  84  (41) 0.7 (0.5-1.1)
DQB1*03 92  (56) 102  (49) 1.3 (0.9-2.0)
DQB1*04   9    (5)   10    (5) 1.1 (0.5-2.8)
DQB1*05 56  (34)   65   (31) 1.1 (0.7-1.8)
DQB1*06 74  (45)    96   (46)  1.0 (0.6-1.4)
GBS: Guillain-Barré syndrome, OR: odds ratio and 95% CI: 95% confidence interval.
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HLA-DRB1 and –DQB1 alleles in relation to clinical and serological 
characteristics
When occurrence of  HLA-DRB1 and DQB1 was compared to prodromal illness, 
antecedent infections (C. jejuni, CMV, EBV and M. pneumoniae), severity of  disease, 
requirement of  mechanical ventilation, cranial and sensory nerve deficits, prognosis 
and electrophysiological subgroups, there was a significant association between the 
presence of  the HLA-DRB1*01 allele (HLA-DR1) and the requirement of  mechanical 
ventilation. Forty-four percent of  the ventilated patients were DR1 positive compared 
to only 16% of  the non-ventilated patients (OR 4.2, 95% CI 1.9-9.6, p
u 
<0.001 and 
p
c
=0.02; table 3). We also compared the difference in the percentage of  patients 
requiring mechanical ventilation between the DR1+ group and DR1- group of  patients 
at different time points (Figure 1). A higher percentage of  patients within the DR1+ 
group needed mechanical ventilation 1 week after randomization compared to the 
DR1- group (p=0.001).
Figure 1.
HLA-DRB1*01 allele is associated with mechanical ventilation. Percentage of  GBS patients requiring mechanical 
ventilation in the HLA-DR1+ group (black square; n=28) versus HLA-DR1– group (black triangle; n=118) represented 
at 13 time points during a follow-up of  26 weeks.
* Significant difference between HLA-DR1+ group versus HLA- DR1 – group (p=0.001).
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DR1 was also associated with the presence of  cranial nerve deficits, but this 
association did not reach significance after correction for multiple testing (see Table 3). 
To further evaluate the clinical relevance of  the association between HLA-DRB1*01 
allele and the need for mechanical ventilation, we performed a univariate logistic 
regression analysis on the following variables: age, sex, HLA-DR1, MRC-sumscore at 
entry, cranial nerve deficits and C. jejuni and CMV infection. The following variables 
showed a significant positive effect: HLA-DR1, MRC-sumscore at entry and cranial 
nerve deficits (all p < 0.005). We included these variables in a multivariate logistic 
regression model and all variables showed a p value of  < 0.05, indicating that the 
association between HLA-DR1 and mechanical ventilation was independent of  the 
severity of  paresis and the presence of  cranial nerve deficits.
The frequency of  the HLA-DRB1*04 allele was increased in the group of  
patients who had diarrhea, but this association did not reach significance. We also 
observed several associations between the presence of  anti-ganglioside antibodies and 
HLA-class II alleles, but these associations did not reach significance (Table 3). 
Review of previous case-control studies on HLA-distribution in 
GBS
To our knowledge 17 case-control studies investigating HLA-distribution in GBS 
patients have been reported. The ethnic origin, number of  patients and controls 
studied, subgroups and associations are listed in table 1 (see also Table E-1 on the 
Neurology Web site). In the Discussion, these data are compared with the results of  
our current study.
Table 3. HLA class II allele distribution in clinical and serological subgroups of GBS. 
 HLA-association*  HLA-allele frequency †  pc-value 
‡
   positive (%) negative (%)   
Antecedent infection
diarrhea DRB1*04 19/48 (40) 20/94  (21) 0.49
Campylobacter jejuni none
Anti-ganglioside antibodies
anti-GM1,GQ1b, GM2 or GD1a DRB1*03 16/28 (57) 37/114 (32) 0.65
anti-GM1 DRB1*04   6/49 (12) 26/93  (28) 0.57
anti-GQ1b DRB1*04 12/49 (24)   8/93   (9) 0.31
anti-GM2 DRB1*08   3/8   (38) 9/134   (7) 0.38
Clinical features
mechanical ventilation DRB1*01 15/34 (44) 19/122 (16) 0.02
MRC-sumscore < 40/60 none
F-score ≥ 3 none
cranial nerve deficits DRB1*01  24/31 (77) 56/111 (50)  0.14
* An uncorrected p-value <0.05 is used to identify possible HLA-associations. † The frequency of  the selected HLA-
allele within a subgroup of  GBS patients is compared between patients with or without the mentioned characteristic. 
‡ P
c
-value: p-value corrected for testing multiple alleles.
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Discussion
In the last three decades, 17 case-control studies have investigated whether there 
is an association between HLA-class I or II antigens and GBS susceptibility and 
subgroups (Table 1 and Table E-1 on the Neurology Web site).16-32 With regard to 
disease susceptibility, most of  the studies did not find any association or at most only a 
weak association that could not be confirmed by other studies. In our study, involving 
the largest group of  Caucasian GBS patients evaluated thus far, we could not find 
an association between HLA-DR and HLA-DQ molecules and disease susceptibility 
either. Thus, we can conclude that the HLA-system probably does not play a general 
role in the susceptibility to develop GBS.
However, as GBS is a very heterogeneous disorder in which the underlying 
immunological mechanisms could be different in the different clinical subgroups, 
analysis of  these subgroups is potentially a better approach than studying the group as 
a whole. Within our well-documented cohort of  GBS patients we report an association 
between the presence of  the HLA-DRB1*01 allele and the requirement of  mechanical 
ventilation, which has not previously been reported. This association was independent 
of  the severity of  paresis and cranial nerve deficits, this last was used as a variable in 
the multiple regression analysis, since cranial nerve involvement was weakly associated 
with HLA-DRB1*01. Moreover, deficits of  the bulbar nerves could cause dysphagia 
leading to a pneumonia and mechanical ventilation. HLA-DR1 has not previously 
been demonstrated to be associated with artificial respiration or respiratory distress. 
The association between HLA-DRB1*01 and mechanical ventilation might be related 
to the presentation of  a pathogen-derived peptide in the pocket of  the HLA-DR1 
molecule itself. Alternatively, this association might be indirectly due to other immune-
regulatory genes located within the HLA system, such as TNF-alpha and complement 
factors.33 In theory, the association could also be merely due to multiple-testing bias 
and it therefore requires independent confirmation in another well-defined and large 
group of  Caucasian GBS patients. 
Inconsistent HLA associations have been reported for C. jejuni infected GBS 
patients, the presence of  certain anti-ganglioside antibodies and electrophysiological 
characteristics (Table 3 and (E)T-1). Briefly, GBS after a C. jejuni infection was 
associated with HLA-DQB1*03 in a Caucasian group29, while in a Japanese group it 
was associated with HLA-B54 and Cw1.22 The frequency of  HLA-DRB1*0803 was 
increased in Japanese GBS patients with anti-GM1 antibodies25, while in Chinese 
patients HLA-DQA1*0301 was increased, but neither significantly.24 We could not 
confirm any of  these associations within our large subgroups of  GBS patients. The 
data obtained from Japanese or Chinese patients may reflect differences in ethnic 
origin, or the occurrence of  AMAN, which is common in Japan and China and rare in 
The Netherlands. In our study, the frequency of  HLA-DRB1*04 was increased in the 
anti-GQ1b positive subgroup and decreased in the anti-GM1 positive subgroup, but 
this difference did not reach significance after correction for testing multiple alleles. 
The tendency towards an association between certain HLA-class II alleles and anti-
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ganglioside antibodies suggests that the production of  anti-ganglioside antibodies may 
be partly dependent on the presence or absence of  certain HLA-antigens. 
In Chinese AIDP patients (n=25) the frequencies of  the HLA peptide motifs 
DQβ ED70-71 and DRβ E9V11H13 were higher, while that of  DQβ RPD55-57 was lower 
compared with the control group.26 Although we did not specifically analyze the 
HLA-peptide motifs, we were able to directly compare our results with these results 
since the peptide motif  DQβ ED70-71 in our population is predominantly present 
in HLA-DQB1*04 alleles and the DRβ E9V11H13 peptide motif  in HLA-DRB1*04 
alleles. The frequencies of  these alleles were not increased in our large group of  AIDP 
patients (n=67) compared to the controls. In general, the results of  all HLA studies 
and GBS subgroup analyses showed only weak associations, if  any, and the results 
are inconsistent. This inconsistency could be based on the small numbers of  patients 
studied, methods used to detect C. jejuni infections and anti-ganglioside antibodies, 
differences in defining clinical patient subgroups and differences in susceptibility due 
to ethnic origin.
Another explanation could be that presentation of  antigens by HLA molecules may 
not be involved in the predisposition to develop GBS after a common infection.
HLA-molecules bind pathogen-derived peptides and present these to T cells, which 
in turn are activated in an HLA-restricted manner. In the pathogenesis of  GBS there 
is no convincing evidence as yet that peptide epitopes of  either the host or pathogen 
play a major role. In an animal model for GBS, experimental autoimmune neuritis, 
the peripheral nerve myelin proteins P
0
,
 
P
2
, PMP-22, myelin-associated glycoprotein 
and myelin basic protein initiate an inflammatory demyelinating response.34 However, 
the pathogenic role of  these proteins in GBS is a matter of  debate.35 In contrast, 
the antibody response in GBS patients is directed against glycolipids instead of  
proteins. In the case of  C. jejuni infected GBS patients, antibodies are directed to lipo-
oligosaccharide present on the outer membrane of  C. jejuni and to gangliosides in the 
peripheral nerves.36, 37 Gangliosides may be presented by CD1b, a nonpolymorphic 
HLA class I-like molecule instead of  classical HLA-class II molecules.38, 39
As some pockets of  the HLA molecules can bind large hydrophobic residues, we 
cannot exclude the possibility that besides CD1b-molecules, HLA molecules also 
present relevant glyco-conjugates and thereby modulate the immune response in 
GBS. This might explain the association between HLA class II allele and requirement 
of  mechanical ventilation and the tendency towards an association with antibody 
responses against individual gangliosides. 
The finding that there is no clear association between HLA-class II and GBS is 
remarkable, considering the well-known HLA associations in classical autoimmune 
diseases. However, it is consistent with the fact that GBS does not have the 
demographic characteristics which are typical for other autoimmune disorders like 
multiple sclerosis and rheumatoid arthritis: (i) in GBS women are not more frequently 
affected than men, (ii) the incidence of  GBS is not highest during the fertile period, but 
instead slightly increases with age, (iii) GBS is a post-infectious disorder, (iv) instead 
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of  a relapsing-remitting course, GBS patients have a monophasic course of  disease, 
and (v) GBS is not associated with other autoimmune disorders. These differences 
further indicate that the pathogenesis of  GBS differs considerably with that of  HLA 
II-related autoimmune diseases.
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Abstract
Objectives: Guillain-Barré syndrome (GBS) is a heterogeneous immune-mediated 
polyneuropathy preceded by common types of  infection. This post-infectious 
autoimmune response is rarely seen suggesting a role for variations in genes encoding 
immune regulatory molecules. In this study we assessed whether single nucleotide 
polymorphisms (SNPs) in the costimulatory genes CTLA4, CD28, CD86, CD40, 
CD40L and ICAM1 are a general susceptibility factor for developing GBS or are 
related to antecedent infection, anti-ganglioside antibodies, neurological deficits, 
severity of  disease and recovery rate.
Methods: 274 Dutch GBS patients, of  whom 154 participated in one of  the Dutch 
treatment trials, and 212 healthy Dutch controls were recruited and their genotypes 
were determined. 
Results: The genotype frequencies did not differ between GBS patients and controls. 
However, the T-allele at position –318 of  the promoter region of  CTLA4 and its 
T-318A+49 haplotype were associated with a mild form of  disease (F-score ≤ 2). The 
T-allele at position –1 of  CD40 was associated with the presence of  anti-ganglioside 
antibodies. 
Conclusion: These associations suggest that genetic variations in costimulatory 
molecules are not a general susceptibility factor, but might modulate the immune 
response in specific subgroups of  GBS. 
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Introduction
Guillain-Barré syndrome (GBS) is the most common form of  acute flaccid paralysis 
in the Western world with a mortality rate of  about 5%. Crucial in the pathogenesis 
of  GBS is the breakdown of  self-tolerance after common types of  infection in 
which molecular mimicry plays an important role.1 The antecedent infections and 
anti-ganglioside antibodies are related to specific clinical patterns of  neurological 
deficits and disease progression.2 This transient autoimmune response after infection 
occurs not generally. Host susceptibility may be explained by genetic polymorphisms 
regulating the immune response. 
Costimulatory molecules play a central role in the activation, maturation, longevity 
and apoptosis of  antigen presenting cells (APC), B-cells and T-cells, and in the 
maintenance of  self-tolerance. An aberrant immune response after a common type 
of  infection could be the result of  an imbalance in the interplay between APC, B 
and T-cells between costimulatory signals (CD86-CD28 and CD40-CD40L) and 
down-regulatory signals (CD86-CTLA-4 interaction).3, 4 The effectiveness of  these 
interactions is promoted by the adhesion molecule ICAM-1. Due to their central role 
in the immune response, some of  these costimulatory molecules are targets for new 
anti-inflammatory strategies in autoimmune disorders and transplantation.3, 4
Single nucleotide polymorphisms (SNPs) within CTLA4 are associated with 
several immune-mediated disorders (reviewed by Kristiansen et al.).5 A SNP in the 
promoter region of  CTLA4, C(-318)T, is associated with a higher promoter activity.6 
The A(+49)G polymorphism within the first exon of  CTLA4 leads to a reduced 
expression of  CTLA-4 and a more pronounced T-cell proliferation.7 Other SNPs 
within the genes encoding costimulatory molecules are the G(+1057)A polymorphism 
in exon 8 of  CD86,8 the polymorphisms G241R in exon 4 and E469K in exon 6 of  
ICAM19 all three resulting in an amino acid substitution, a C/T transition in the Kozak 
sequence (at position –1) of  CD40 10 and the third intron of  CD28 11 and a C(-726)T 
and C(+220)T polymorphisms in CD40L.12 We postulated that these SNPs might 
be a susceptibility factors for the development of  GBS or for specific clinically or 
immunologically defined subgroups of  GBS.
In this study, we assessed whether these SNPs are a general susceptibility factor 
for GBS or are related to specific antecedent infection, anti-ganglioside antibodies, 
neurological deficits, severity of  disease and outcome.
Patients and methods
Two hundred and seventy-four Dutch GBS patients (median age at disease onset 
46 years, range 7-82 years, male/female ratio=1.08) fulfilling the diagnostic criteria 
for GBS were included. This group of  patients consisted of  154 well-documented 
GBS patients who participated in one of  the Dutch GBS trials13, 14, 35 patients 
who participated in an open prospective study15 and 85 patients who have not 
participated in a trial or survey. Detailed information about clinical and serological 
characteristics of  these patients has been described previously. Severe (versus mild) 
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GBS was defined as (1) an MRC-sumscore < 40/60 at nadir or (2) the inability to 
walk independently (F-score of  3, 4 or 5).16 Poor outcome was defined as the inability 
to walk independently after six months of  follow-up. Caucasian healthy blood bank 
donors were used as control group (n=212, median age 35 years, range 19-60 years, 
male/female-ratio=0.66). 
Genotyping was performed using the LightCycler technique (Roche Diagnostics, 
Mannheim, Germany). The set of  primers and hybridisation probes were designed by 
Tib MolBiol (Berlin, Germany). Sequence-verified control donors for each genotype 
were used in every experiment. 
Verification of  Hardy-Weinberg equilibrium and genotype distribution and allele 
frequencies were compared using the Pearson’s Chi-square test. When one of  the cells 
had an expected value less than five, the Fisher’s exact test was used. An expectation-
maximization algorithm was used to test for linkage disequilibrium and to compare 
the estimated haplotype distributions (http://www.mrc-bsu.cam.uk/personal/adrian/
welcome.shtml). P-values < 0.05 were considered to be statistically significant.
Results
All SNPs were in Hardy-Weinberg equilibrium (p>0.2) and the SNPs in CTLA4, 
ICAM1 and CD40L were in linkage disequilibrium (p<0.001). The genotype 
distributions, allele frequencies and the haplotype distributions from the total group 
of  GBS patients did not differ from the healthy controls (Figure 1).  
0%
20%
40%
60%
80%
100%
ICAM1
G241R
ICAM1
E469K
CD40
C/T -1
CD40L 
C(-726)T *
CD40L 
C(+220)T *
CTLA4
C(-318)T
CTLA4
A(+49)G
CD86
G(+1057)A
CD28
IVS3 +17 C/T
P      C              P      C               P      C           P      C              P       C              P      C        P      C              P      C               P      C
Figure 1. Genotype distribution of single nucleotide polymorphisms within costimulatory 
genes in GBS patients and healthy controls. 
No differences in genotype distributions were found between patients (P) and controls (C): homozygotes wild type-
allele, heterozygotes and homozygotes variant allele. CTLA-4: Cytotoxic T-lymphocyte antigen-4. *  The CD40L 
gene is located on the X-chromosome. Since men have only one allele, only the genotype distribution of  women is 
represented. 
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When GBS patients were subdivided with regard to the severity of  disease based 
on the F-score at nadir, 14 patients were mildly affected and 180 patients were severely 
affected. In the group of  mildly affected patients the T-allele at position –318 of  the 
promoter region of  CTLA4 was more frequently found compared to the severely 
affected patients (OR = 4.0, 95% CI =1.6 to 10.0, p = 0.001). The haplotype analysis 
showed that in this group of  mildly affected GBS patients the T-319A+49 was more 
frequently found (Table 1). Based on the MRC-sumscore, we did not observe any 
differences in genotype distribution between mildly and severely affected patients.
In the group of  patients whose serum was screened for the presence of  anti-
ganglioside antibodies, 74 patients had detectable levels of  anti-ganglioside antibodies 
(directed to GM1, GQ1b, GD1a and/ or GM2) and 108 patients did not have 
detectable of  these antibodies. The T-allele at position –1 of  the CD40 was more 
frequently found in patients with anti-ganglioside antibodies compared with those 
without these antibodies (29% vs. 18.9%, OR (95% CI = 1.8 (1.1-3.0); p=0.02). 
The genotype distribution between these subgroups, however, was not significantly 
different (p=0.065).
No other differences were found between the studied SNPs and age, sex, 
antecedent infection and outcome.
Table 1.  CTLA4 polymorphisms in mildly versus severely affected GBS patients.
SNP  
mildly affected 
(n=14)  
severely affected 
(n=180)  OR (95% CI)  p-value
F-score < 3 F-score ≥ 3
  %  %     
CTLA4 C(-318)T
CC 50.0 82.8 reference 0.007
CT 42.9 16.1 4.4 (1.3-14.3)
TT 7.1 1.1 2.4 (0.2-32.3)
CTLA4 A(+49)G
AA 42.9 36.1 reference NS
AG 42.9 50.6 0.7 (0.2-2.4)
GG 14.3 13.3 0.9 (0.2-4.9)
CTLA4 -318/+49
CA 35.7 52.2 reference 0.04
CG 35.7 38.6 1.4 (0.6-3.5)
TA  28.6  9.2  1.1 (0.4-2.9)   
Severity of  disease was based on the functional disability score (F-score) at nadir. Mildly affected patients are still 
capable of  walking independently, while severely affected patients are not able to walk independently and some need 
artificial respiration. Fisher’s exact test was used to compare genotype distributions. OR: Odds ratio, CI: confidence 
interval. CTLA-4: cytotoxic T-lymphocyte antigen-4. 
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Discussion
This study shows that none of  the selected SNPs in the costimulatory molecules is 
a general susceptibility factor for developing GBS after a common infection. This 
lack of  association could be due to the heterogeneity of  GBS and therefore we also 
performed subgroup analysis to assess whether the SNPs contribute to specific 
subgroups of  GBS. We did not observe any associations between any of  the SNPs 
studied and age, sex, antecedent infection, neurological deficits or outcome. 
However, the T-allele at position –1 of  the CD40 was more frequently found 
in patients with anti-ganglioside antibodies compared with those without these 
antibodies. Although the functional effect of  this SNP, CD40 C/T
–1
,has yet not been 
established, it may affect the translational efficiency of  CD40 and thereby influencing 
the CD40-CD40L interaction, which is involved in B-cell, T-cell and macrophage 
activation.10
In the subgroup analysis, we also showed that the T-allele at position –318 of  the 
promoter region of  CTLA4 and the T-318A+49 haplotype are associated with mildly 
affected patients based on the GBS functional disability score (F-score < 3; Table 1). 
This association is mainly due to the presence of  a T-allele at position –318, which 
is associated with a higher promoter activity.6 This allele may therefore contribute to 
an increased expression of  CTLA-4 upon T-cell activation, thereby promoting down-
regulation of  the T-cell response, which may favor a mild form of  disease. An A-allele 
at position + 49 might have the same protective effect, since only the GG genotype 
at this position is associated with a reduced expression of  CTLA-4 and an increased 
T-cell proliferation.7 Interestingly, results from a mouse model for GBS (experimental 
autoimmune neuritis) showed that blockade of  CTLA-4 resulted in enhanced 
incidence and more severe course.17
Both associations reported could theoretically be false positive results due to 
multiple testing biases or in the case of  CTLA-4 and severity of  disease also due to the 
relative small number of  mildly affected patients we studied. Confirmation of  these 
associations in larger subgroups of  patients, especially also in mildly affected patients 
are required. However, given the clear role of  CD40 in B-cell activation, antibody 
production of  different subclasses and augmentation of  T-cell responses, and of  
CTLA-4 in down-regulation of  T-cell responses, these results encouraging functional 
studies.
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Abstract
Complement activation plays an important role in the pathogenesis of  Guillain-
Barré syndrome (GBS). Mannose-binding lectin (MBL) activates the complement 
system via the lectin pathway after recognition of  repetitive sugar groups on 
pathogens. We investigated whether MBL2 genotype, serum MBL level and MBL 
complex activity are associated with the development and severity of  GBS. Single 
nucleotide polymorphisms (SNPs) in the promoter region (-550 H/L and –221 X/Y) 
and exon 1 (A/O) of  the MBL2 gene were determined in 271 GBS patients and 
212 healthy controls. The frequencies of  the H-allele, the HY promoter haplotype 
and the HYA haplotype, which are associated with an increased MBL-production, 
were all increased in GBS patients compared to healthy controls (P ≤ 0.03). These 
associations at genomic level were particularly pronounced in severely affected GBS 
patients (MRC-sumscore < 40) (P ≤ 0.02). Moreover, severe muscle weakness at entry 
was significantly associated with high MBL concentrations and high MBL complex 
activity in sera from GBS patients (P < 0.01). These results favour the hypothesis that 
complement activation mediated by MBL contributes to the extent of  nerve damage 
in GBS, which is co-determined by the MBL2 haplotype.
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Introduction
Guillain-Barré syndrome (GBS) is a post-infectious immune-mediated polyneuropathy 
characterized by a monophasic subacute paresis and sensory deficits. It has been 
hypothesized that antecedent infections in susceptible hosts induce cross-reactive 
antibodies to peripheral nerve gangliosides, resulting in antibody-mediated 
complement activation and subsequent nerve damage.1
Complement activation seems to play a crucial role in the pathogenesis of  
GBS. In GBS patients, complement activation products are elevated in serum and 
cerebrospinal fluid.2-4 Deposits of  activated complement factors, C3d and C5b-9, are 
found on the outer membrane of  Schwann cells in acute inflammatory demyelinating 
polyneuropathy (AIDP)5, and on the axolemma of  motor fibres in acute motor axonal 
neuropathy (AMAN).6 In the mouse diaphragm-phrenic nerve model in which the 
pathophysiological effects of  antibodies can be studied, complement activation is 
crucial for induction of  electrophysiological alpha-latrotoxin-like effects by anti-
GQ1b-antibodies and for nerve cytoskeletal damage.7, 8 Recently, the complement 
dependency of  the pathogenic effect of  anti-ganglioside antibodies was confirmed 
in an in vitro assay with neuronal cells expressing gangliosides.9 Furthermore, the 
beneficial effect of  intravenous immunoglobulin (IVIg) treatment in GBS is likely to 
be partly due to the prevention of  complement activation.10
The complement system can be activated via three different pathways: the classical, 
alternative and lectin pathway. The lectin pathway can be activated via mannose-
binding lectin (MBL), a C-type lectin that is primarily synthesized in the liver and 
that recognizes repetitive sugar groups such as mannose and N-acetyl-glucosamine 
on the surface of  bacteria and viruses.11, 12 Binding of  these sugar groups leads to 
complement activation and opsonization of  the pathogens with C4b and C3b, thereby 
facilitating phagocytosis. Furthermore, MBL recognizes structures on apoptotic cells 
and facilitates the clearance of  these cells by macrophages.13, 14
Serum levels and the functional activity of  MBL are highly variable in the human 
population. This variation is mainly determined by single nucleotide polymorphisms 
(SNPs) located in the promoter region and in exon 1 of  the MBL2 gene.15-17 SNPs 
in exon 1 affect the polymeric structure of  the MBL molecule, resulting in low 
serum levels of  MBL and an impaired ability to activate the complement system.18 
Furthermore, two SNPs in the promoter region affect the levels of  MBL by regulating 
the transcriptional activity of  the MBL2 gene: the -550 H/L polymorphism and -221 
X/Y polymorphism.19, 20 
Given the role of  MBL in pathogen recognition and opsonization, complement 
activation and clearance of  apoptotic cells, we hypothesized that the functional activity 
of  the lectin pathway partly determines the susceptibility to develop GBS and/or the 
extent of  nerve damage in GBS. Therefore, we assessed the association of  the MBL2 
genotype, MBL serum levels and MBL functional activity with GBS susceptibility and 
severity. 
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Patients & Methods
Study population
In this study peripheral blood samples were obtained from 271 Dutch Caucasian 
GBS patients (median age at onset of  disease 46 years, range 7-82 years, male/female 
ratio=1.06) who participated in one of  the Dutch trials or national survey studies.21-24 
All patients fulfilled the diagnostic criteria for GBS.25 The protocol of  this study was 
reviewed and approved by the Medical Ethical Committee of  the Erasmus MC, and all 
patients gave their written informed consent. Of  these patients 153 participated in one 
of  the Dutch GBS trials and are therefore documented in detail.22, 23 At randomisation 
these patients were clinically examined and pre-treatment blood samples were obtained 
for screening for the most common antecedent infections in GBS (Campylobacter jejuni, 
cytomegalovirus, Epstein-Barr virus and Mycoplasma pneumoniae) and the presence of  
anti-GM1 and anti-GD1a antibodies.26, 27 Sera were all tested in 1:100 dilutions in 
ELISA and were considered to be positive according to criteria defined previously.27 
During a follow-up of  six months, the patients were neurologically examined on 13 
to 16 time points according to the protocol. The Medical Research Council (MRC)-
sumscore (ranging from 0-60),28 the GBS disability F-score,29 and the involvement of  
sensory and cranial nerves were assessed at these time points. Severe (versus mild) 
GBS was defined as (1) an MRC-sumscore < 40 at nadir30 or (2) the inability to walk 
independently (F-score of  3, 4 or 5).31
Genomic DNA of  212 Dutch Caucasian healthy subjects (median age 35 years, 
range 19-60 years, male/female-ratio=0.65) was provided by the Laboratory for 
Histocompatibility and Immunogenetics, Sanquin Bloodbank South West Region, 
Rotterdam, The Netherlands. All healthy subjects had given a written informed 
consent. 
Isolation of genomic DNA
Isolation of  genomic DNA from EDTA anti-coagulated blood samples was 
performed using the Invisorb® MaxiBlood kit (Invitek, Berlin, Germany) according to 
the manufacturer’s instruction. The DNA samples were dissolved in 0.1x TE-buffer 
and stored at -80°C. 
Detection of polymorphisms in the promoter region and exon 1 of 
the MBL2 gene 
In this study we detected the (-550) H/L and (-221) X/Y polymorphism in the 
promoter region of  the human MBL2 gene in a single LightCycler (Roche 
Diagnostics, Mannheim, Germany) assay with two sets of  hybridisation probes 
(TibMolBiol, Berlin, Germany). The forward primer 5’-GCCAGAAAGTAGAGA
GGTATTTAGC-3’ and the reverse primer 5’ TGTGACATGCGTGACTAGTAC-
3’ were used to amplify a fragment spanning the two SNPs in the promoter 
region. For genotyping the H/L polymorphism at position –550, we used the 
fluorescein-labelled detection probe 5’-TTTTAGACAGGCTTGCCTGGGT-
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3’FLU which is complementary to the L allele and the 5’-LC Red 705- AGCATTT
TCTCTGGAAATTTCTTACTACGTTGG-3’-phosphorylated anchor probe. The 
5’-CTATAAACATGCTTTCGGTGGCAGT-3’FLU detection probe and the 5’-LC 
Red 640- AACAAATGGGACCGTGCATTGCCA-3’-p anchor probe were used for 
genotyping the X/Y SNP.
In another assay, the three SNPs in codon 52, 54 and 57 in exon 1 were detected 
using one set of  hybridisation probes. The area of  the MBL2 gene spanning exon 1 
was amplified by using the forward primer 5’ TGAGTATGGTCAGCGTCTTA-3’ 
and the reverse primer 5’ TGGGCTGGCAAGACAACTATTAG-3’. The 5’-LC-Red 
640-TTCTTCCTTGGTGCCATCACACCCA-3’-p detection probe and the 
fluorescein-labelled anchor probe 5’-CAGCCCAACACGTACCTGGTTCCCCCT-
3’FLU were used to detect the three SNPs in exon 1 (TibMolBiol). The “A”-allele 
represents the wild type, while the “O” allele represents the variant alleles B, C, and 
D together. 
The PCR-reaction and the melting curve were performed in LightCycler capillaries 
(Roche Diagnostics) with a final volume of  20 µl, containing 10ng genomic DNA, 
0.5 µM of  each primer, 0.15 µM of  each hybridisation probe, 1x LightCycler DNA 
Master Hybridisation Probes (Roche Molecular Biochemicals, Mannheim, Germany) 
and 2 mM MgCl
2
. The PCR amplification profile of  both experiments consisted of  10 
min at 95°C, followed by 45 cycles of  95°C for 3 sec, 60°C (63°C in case of  detection 
of  the MBL exon 1 polymorphism) for 15 sec and 72°C for 10 sec. Next, the melting 
curve profile was performed, which consisted of  1 cycle of  95°C for 3 min, 55°C for 
1 min, 45°C for 30 sec and 40°C for 3 min after which the temperature was slowly 
increased (0.1°C/sec) to 80°C under continuous detection of  the emitted light. Data 
were analysed using the melting curve program. In each experiment we used sequence-
verified control donors for each genotype.
Detection of MBL concentration in serum
MBL concentration levels were measured in pre-treatment serum samples from 
82 randomly selected GBS patients. Fifty-one of  these patients were mildly and 31 
severely affected based on the MRC-sumscore at nadir. Anti-ganglioside antibodies 
directed to GM1 and/or GD1a were present in 58 patients and absent in 23 of  these 
patients. Additionally, in eight randomly selected GBS patients MBL concentrations 
were measured in follow-up serum samples obtained at 2 weeks, 4 weeks, 3 months 
and 6 months after randomisation. Since IVIg is the standard therapy for GBS patients, 
an IVIg solution preparation (Gammagard SD, Baxter Healthcare, Hyland Division) 
was tested for the possible presence of  MBL. MBL concentrations were determined 
using a human MBL oligomer ELISA kit (Antibodyshop, Gentofte, Denmark), which 
specifically detects oligomerized forms of  MBL. The ELISA and the calculation of  
the concentrations were performed according to the manufacturer’s instruction.
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Detection of MBL complex activity
To assess the MBL complex activity we determined the specific C4b-depositing 
capacity of  the MBL-pathway in serum from the randomly selected GBS patients 
(n=78; serum from 2 mildly and 2 severely affected patients was not available anymore) 
by using an ELISA-based method as described before32 with slight modifications. In 
short, Maxisorb microtiter wells (Nunc, Kamstrup, Denmark) were coated with 10 µg 
mannan (Sigma, St. Louis, Missouri) in 100 µl of  coating buffer (100mM NaHCO
3
,
 
100 mM Na
2
CO
3
,
 
pH 9.6) and incubated overnight at room temperature (RT). After 
this coating step plates were washed three times with PBS/0.05 % Tween 20. To avoid 
non-specific binding, plates were blocked with PBS-1% BSA during 1 h at 37°C. All 
samples were diluted in cold GVB++ buffer (veronal buffered saline, 0.08% gelatine, 2 
mM CaCl
2
, 1 mM MgCl
2
 and 0.05% Tween 20) containing 1M NaCl, overnight at 4°C. 
Plates were washed with PBS/0.05% Tween 20 containing 5 mM CaCl
2
, followed by 
incubation with purified C4 (1 µg/ml), diluted in GVB++, for 1 h at 37°C. Activation 
of  C4 was assessed as described.18
Statistical analyses 
Pearson’s chi-square test was used to verify whether the SNPs were in Hardy-Weinberg 
equilibrium and to compare the genotype, allele and haplotype frequencies between 
patients and healthy subjects. Conditional logistic regression was used to determine 
the independent contribution of  each SNP. The Mann-Whitney U test was used to 
compare MBL concentrations and complex activities in mildly versus severely affected 
GBS patients. The Spearman rank correlation coefficient was used for correlation 
analyses. The Friedman test was used to compare the MBL levels in follow-up serum 
samples from individual patients. The Wilcoxon sign rank test was used to compare 
MBL-concentrations in follow-up serum samples at two different time points. 
Probability (P) values ≤ 0.05 were considered to be statistically significant.
Results 
Genotype, allele and haplotype frequencies in GBS patients and 
controls: MBL2 gene polymorphism is a susceptibility factor for 
GBS
In this study we determined the polymorphisms in the promoter region and exon 1 of  
the MBL2 gene in 271 GBS patients and 212 healthy subjects. Since all SNPs were in 
Hardy-Weinberg equilibrium (P > 0.3) and in linkage disequilibrium (P < 0.001), we 
were able to compare the genotype, allele and haplotype frequencies between GBS 
patients and healthy controls. The genotype distribution of  the H/L SNP at position 
–550 of  the promoter region and the haplotype distributions were different between 
GBS patients and healthy controls (P = 0.004 and P = 0.02 respectively; Table 1). 
GBS patients had significantly higher frequencies of  the H-allele, HH genotype, HY 
promoter haplotype and the HYA haplotype (all P-values ≤ 0.03). The differences 
in haplotype distributions were mainly due to the presence of  an H-allele at position 
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–550 of  the promoter region, which was independent of  the SNPs in exon 1 
(P = 0.001). The relation between the number of  H-alleles or HYA haplotypes and 
disease susceptibility is best described by a multiplicative model: the presence of  one 
H-allele or HYA haplotype was associated with an increased risk for GBS, but the 
presence of  two H-alleles or HYA haplotypes increased this risk even more (P ≤ 0.03). 
Together, these data indicate that the susceptibility for GBS is associated with MBL2 
genotypes that promote high production of  MBL.
The distribution of  exon 1 variant alleles did not significantly differ between 
patients and controls. In the control group, the frequencies of  the four different exon 
1 alleles were: 75.7% (A-allele = wild-type), 15.6% (B-allele), 1.9% (C-allele) and 6.8% 
(D-allele). In GBS patients these frequencies were 76.6 % (A-allele), 13.2% (B-allele), 
2.0% (C-allele) and 8.2% (D-allele). The X/Y promoter SNP at position –221 also did 
not significantly differ in genotype distribution between GBS patients and controls. 
The Y-allele was present in 77.1% of  the controls and in 80.4% of  the GBS patients. 
Genotype, allele and haplotype frequencies are associated with a 
severe form of GBS
Considering the significant differences in genotype and haplotype frequencies between 
GBS patients and controls and the heterogeneity of  GBS, we searched for correlations 
between MBL2 SNPs and clinical and serological subgroups of  GBS patients. The 
genotype distribution of  the H/L SNP at position –550 of  the promoter region and 
the haplotype distributions were different between severely affected (MRC-sumscore 
< 40) and mildly affected (MRC-sumscore ≥ 40) GBS patients (P = 0.02 and P = 0.04 
respectively; Table 1). The frequencies of  the H-allele, HH and HL genotype and 
HY promoter haplotype (all P-values ≤ 0.02) were significantly increased in severely 
affected GBS patients. The MBL2 haplotype frequencies did not differ between 
severely and mildly affected patients. 
The frequencies of  these genotypes and haplotypes did not differ between the 
mildly affected GBS patients and healthy controls. However, the genotype distribution 
(P < 0.001) and haplotype distributions (P ≤ 0.02) were significantly different between 
severely affected GBS patients and healthy controls. The frequencies of  the H-allele, 
HH genotype, HY promoter haplotype and HYA haplotype were significantly increased 
in severely affected GBS patients (all P-values ≤ 0.02). The observed differences in 
haplotype distribution were mainly due to the presence of  an H-allele at position 
–550 of  the promoter region, which effect was independent of  the SNPs in exon 1 
(P < 0.001). To describe the relation between the number of  H-alleles and HYA-alleles 
and the severity of  GBS, a multiplicative model was the best-fitted model (P < 0.02). 
These data indicate that the MBL2 haplotypes that promote high production of  MBL 
are mainly a susceptibility factor for getting a severe form of  GBS. 
In further subgroup analyses, the O-allele was more frequently found in the group 
of  patients with a positive serology for either C. jejuni, CMV, EBV or M. pneumoniae 
(30.4% versus 19.2%, P = 0.02), but not with a positive serology for one antecedent 
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infection in particular. The SNPs in the MBL2 promoter and exon 1 were not 
associated with sex, age, sensory and cranial nerve deficits, severity of  disease based 
on the GBS functional disability score, need for artificial respiration and the presence 
of  antibodies to GM1 and/or GD1a. 
MBL serum levels and MBL complex activity in relation to 
genotypes
In order to establish the functionality of  the SNPs we studied the MBL2 genotype 
in relation to the serum MBL concentration and functional activity of  MBL in GBS 
patients. The MBL complex activity was highly correlated with MBL concentrations 
in serum samples from 78 GBS patients (Figure 1A). The MBL concentrations 
were significantly different when comparing the genotypes of  exon 1. Highest 
concentrations were found in A/A homozygotes (median level 2950 ng/ml), 
intermediate concentrations in A/O heterozygotes (median level 620 ng/ml) and 
lowest concentrations in O/O homozygotes (median level 30 ng/ml; P < 0.0001, data 
not shown). Similar differences were observed for the median level of  MBL complex 
activity: highest in A/A homozygotes (386 U/ml), intermediate in A/O heterozygotes 
(66 U/ml) and undetectable in O/O homozygotes (Figure 1B). As previously 
described 19, also the polymorphism at position –550 of  the promoter region affected 
the MBL concentration. The median concentration of  MBL was higher in H/H 
homozygotes (3450 ng/ml) compared to L/L homozygotes (1160 ng/ml; P = 0.02, 
data not shown). A similar difference was found with respect to MBL function: 
median complex activity of  372U/ml in H/H homozygotes versus 133 U/ml in L/L 
homozygotes (Figure 1C). 
High MBL concentrations and MBL complex activity are associated 
with severe form of GBS 
Since we observed an association between MBL2 haplotypes that promote high 
MBL production and a severe form of  GBS, we examined the relation between 
MBL serum concentration and complex activity and the severity of  GBS. High MBL 
concentrations were associated with low MRC-sumscores at entry (R = -0.27; P = 0.01, 
data not shown). The same trend was found between high MBL concentration and 
low MRC-sumscores at nadir, although this association was not significant (R = -0.20; 
P = 0.07, data not shown). Furthermore, high MBL complex activity was associated 
with low MRC-sumscores at entry (P = 0.009; Figure 2A) and at nadir (P = 0.04; 
Figure 2B). The MBL-complex activity was also significantly higher in the severely 
affected patients compared to the mildly affected GBS patients (Table 2).
Since the presence of  antibodies directed to GM1 or GD1a is also associated 
with a severe weakness in GBS, we compared the MBL concentrations and complex 
activity in patients with or without these antibodies. The MBL concentration and 
MBL complex activity were significantly higher in the group of  patients with these 
antibodies than patients lacking these antibodies (Table 2). 
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MBL serum levels during the disease course
The kinetics of  MBL concentrations was determined in serum samples from eight 
randomly selected GBS patients during a follow-up of  six months. Nadir of  MRC-
sumscore was reached at entry in six patients and at 14 days after entry in two patients. 
The median MRC-sumscore at nadir was 44.5, ranging from 13 to 50. The median 
MRC-sumscore after six months of  follow-up was 57, ranging from 45 to 60. The 
MBL levels changed significantly during follow-up (P < 0.001; Figure 3). Compared 
to pre-treatment samples, MBL levels were significantly higher in serum obtained at 
2 weeks (1.2-fold increase, P = 0.02) and significantly lower in serum obtained at six 
months (1.8-fold decrease, P = 0.03). IVIg preparations contained no detectable levels 
of  MBL (data not shown).
Discussion
Antecedent infection in combination with genetic host factors most likely precipitate 
the cross-reactive immune response and deposition of  activated complement factors 
at peripheral nerves in GBS. MBL plays a crucial role in both pathogen recognition 
and activation of  the complement system and may be one of  the host factors in the 
susceptibility to develop GBS. In the present study we show that the frequencies of  
MBL2 haplotypes that promote high levels of  MBL are increased in GBS patients, in 
particular in those patients with a severe paresis. The patients with a severe paresis 
also had high serum MBL levels and complex activity. MBL activity determined by 
MBL2 gene polymorphisms may therefore contribute to the extent of  peripheral 
nerve damage in GBS.
MBL serum levels and complex activity are mainly determined by MBL2 
polymorphisms. In this study we studied in a large group of  Dutch Caucasoid GBS 
patients the SNPs in the MBL2 gene which are known to influence the serum MBL 
Table 2. Serum MBL concentration and MBL complex activity in subgroups of
    patients.
 severity of  disease P-value anti-ganglioside antibodies P-value
 severe (n=31)* mild (n=51)  present (n=23)* absent (n=58)  
MBL concentration 3324.9 2506.4 0.08 4088.3 2308.9 0.04
(ng/ml) (+/- 522.7) (+/- 418.0) (+/- 792.0) (+/-322.1)
MBL complex activity 336.8 222.7 0.01 373.2 214.4 0.02
(U/ml) (+/- 40.6) (+/- 32.4) (+/-54.3) (27.7)
MBL concentration (ng/ml) and MBL complex activity (U/ml) are represented by mean value and the standard error 
of  the mean between brackets. Severely weakness defined as having an MRC-sumscore < 40 and mild weakness as 
an MRC-sumscore ≥ 40. The presence of  anti-ganglioside antibodies was defined as the presence of  IgM or IgG 
antibodies directed to GM1 or GD1a. *MBL-complex activity was determined in 78 GBS patients: 29 severely and 49 
mildly affected GBS patients and 23 GBS patients with and 54 patients without anti-ganglioside antibodies. 
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levels and functional activity. We did not investigate the +4 P/Q SNP at the 5’ 
untranslated region of  exon 1, since the LYPA haplotype is almost absent in Caucasoid 
individuals and the Q-variant is only present in combination with the LY promoter 
haplotype.19 A recent paper reported other SNPs in a haplotype block at the 3’ end of  
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Figure 1. 
MBL serum concentration in relation to MBL complex activity in GBS patients (N=78) (A). The two 
outliers with no detectable MBL concentrations despite the presence of  MBL complex activity represent 
two patients with a LXA/LXA haplotypes. MBL2 exon 1 genotypes in relation to MBL complex activity 
(B) in GBS patients. MBL2 promoter genotype at position –550 in relation to MBL complex activity 
(C). The thick black line represents the median MBL serum level and complex activity. The dotted lines 
represent the detection limits of  the assays.
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Figure 3.  
MBL serum levels during a follow-up of  six months in eight GBS patients. 
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Figure 2. 
MBL complex activity in relation to the extent of  muscle weakness (MRC-sumscore) measured at entry 
(A) or nadir (B) in GBS patients (N=78). The MRC-sumscore ranges from 0 (tetraparalysis) to 60 
(normal). The dotted lines represent the detection limits of  the assays.
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the MBL2 gene of  which the functional effects on MBL have not been established.33  
The observed genotype frequencies in our healthy control group and the high 
associations between genotype/haplotype and serum MBL levels and complex 
activity in GBS patients are consistent with the findings of  others in healthy controls, 
indicating that our data on genomic, serum and functional level are accurate and 
representative.18, 19, 34, 35
The high frequencies of  the HH genotype and HY and HYA haplotypes in GBS 
patients, particular in severely affected GBS patients, were largely determined by 
the presence of  an H-allele at position -550 of  the promoter region and not by the 
other polymorphisms. The H/L and X/Y alleles have a direct effect on MBL2 gene 
expression by regulating the transcriptional activity. The strong association between 
the H-allele, HYA haplotype and severe disease in GBS patients most likely reflects a 
role for high production of  functional MBL, which was confirmed at serum protein 
and functional level. 
Our data showed that patients with MBL deficiency, characterized by undetectable 
MBL complex activity, show a mild weakness, with MRC-sumscores above 40 at entry. 
The inverse correlation between MRC-sumscores and MBL functional activity may 
indicate that patients only develop a severe form of  GBS when a certain threshold 
level of  MBL is present. MBL levels usually increase upon infection, since MBL is 
an acute phase protein. This acute monophasic response was also found in follow-up 
serum samples from GBS patients, which showed an initial rise in MBL in the acute 
phase and a decline to baseline 6 month after onset of  disease. This transient rise in 
MBL most likely is related to an acute phase response after infection, but could not 
explain the relation between high MBL levels and GBS or the extent of  peripheral 
nerve damage. During acute phase reactions MBL levels may rise up to 3-fold. The 
more than 1000 fold differences in MBL levels found in the pretreatment serum 
samples from the GBS patients could only be explained by genetic variation.12 
High levels of  MBL may exert its effects both at the afferent and efferent part of  
the immune response leading to peripheral nerve damage in patients with GBS. 
(i) MBL binds to repetitive sugar residues on a broad range of  pathogens, thereby 
possibly enhancing the immune response to antecedent bacterial and viral infections 
associated with GBS. Activation of  the complement system facilitates phagocytosis 
by opsonization and enhances antigen presentation and antibody production.12, 36 
This may increase the susceptibility to develop a cross-reactive immune response to 
peripheral nerves after infection. Accordingly an association between high MBL levels 
and the presence of  antibodies to GM1 and GD1a was found, which are known to be 
frequently cross-reactive with infectious agents and are associated with severe GBS.
(ii) MBL may also be involved in the efferent part of  the immune response by 
inducing or enhancing tissue damage. MBL can activate the lectin pathway upon 
recognition of  antibodies of  the IgA subclass37 and of  non-galactosylated IgG 
antibodies38 or might activate this pathway upon recognition of  carbohydrate clusters 
formed via cross-linking of  gangliosides by anti-ganglioside antibodies. Moreover, 
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MBL is able to bind directly to apoptotic and necrotic cells14. Binding of  MBL to 
damaged endothelium following hypoxia is involved in complement activation and 
tissue damage following ischemia/reperfusion injury.39 Recently, a role for MBL in 
tissue injury has been suggested for several inflammatory diseases such as rheumatoid 
arthritis,40 ulcerative colitis41 and diabetic vasculopathy.42 Moreover, a recent report 
demonstrated an association between high levels of  MBL and chronic rheumatic heart 
disease in patients previously diagnosed with rheumatic fever.43 GBS and rheumatic 
fever share the important role of  antecedent infections, molecular mimicry and cross-
reactive antibodies in the pathogenesis. High MBL levels may further trigger these 
post-infectious complications further as indicated by this paper and our manuscript. 
Therefore, the association between MBL and the severity of  GBS shown in the 
present study might be explained by binding of  MBL to initially damaged nerve tissue, 
followed by complement activation, attraction of  inflammatory cells, and aggravation 
of  tissue injury.
The overlap in MBL levels between mildly and severely affected GBS patients 
illustrates the complexity and heterogeneity of  GBS. If  complement activation indeed 
plays such an important role in the pathogenesis, the extent of  peripheral nerve 
damage and motor deficits will also depend on local regulatory components, such as 
complement-inhibitory molecules like the decay-accelerating factor (CD55). Moreover, 
other host factors like higher age at onset and environmental factors such as C. jejuni 
infection have already been shown to be prognostic factors for the development of  a 
severe weakness.26, 30
In conclusion, our study demonstrates an association between MBL2 gene 
polymorphisms and severity of  GBS. The higher levels of  MBL protein and complex 
activity in patients with severe GBS associated with these polymorphisms further 
suggests that complement activation mediated by MBL contributes to the extent of  
nerve damage in GBS. Since the lectin pathway can be involved in several phases 
of  the immune response, further studies are warranted to elucidate the underlying 
mechanism.
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Abstract
In this study we assess in a large cohort of  Guillain-Barré patients (n=262) whether 
eight SNPs in genes encoding macrophage related inflammatory mediators are related 
to the development of  GBS or to specific clinical or immunological subgroups. A SNP 
in TNF-α and a SNP in MMP-9 were associated with severe weakness (MRC-sumscore 
< 40) and poor outcome (not able to walk unaided after 6 months), suggesting that 
these SNPs might be one of  the factors contributing to a severe form of  GBS. 
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Introduction 
Macrophages play a crucial role in demyelination and axonal degeneration in 
respectively the acute inflammatory demyelinating neuropathy (AIDP) and acute 
motor axonal neuropathy (AMAN) variants of  Guillain-Barré syndrome (GBS).1 
Macrophages are guided to their target sites by complement-receptors, Fcγ-receptors 
and complement chemotaxis, and exert their functions by the release of  cytokines 
and other inflammatory mediators. Tumor necrosis factor-alpha (TNF-α), matrix 
metalloproteinase 9 (MMP-9) and nitric oxide synthetase (iNOS) induced nitric oxide 
(NO) play a role in leucocyte attraction, extracellular matrix degradation, demyelination 
and axonal degeneration. Other mediators like urokinase-type plasminogen-activator 
(uPA) and its inhibitor plasminogen activator inhibitor 1 (PAI-1) may also be involved 
in blood-nerve breaching. IL-10, another mediator released by macrophages, may 
exert pro-inflammatory as well as anti-inflammatory effects, since it promotes 
antibody production as well as the termination of  inflammatory response and tissue 
destruction.2 Interactions between macrophages, these mediators and blood-nerve 
barrier may contribute to the extent of  nerve damage. 
Single nucleotide polymorphisms (SNPs) in genes encoding these mediators and 
affecting its levels or functions may be susceptibility factors for macrophage-induced 
nerve damage in GBS. Previous studies showed that elevated levels of  TNF-α 
and MMP-9 are associated with disease severity and electrophysiological changes 
in GBS patients.3 ,4 Another report showed that a SNP in the promoter region of  
IL-10 associated with high IL-10 production was a susceptibility factor for the onset 
of  GBS.5
In this study we assess whether SNPs in the promoter region of  TNF-α, 
MMP-9, IL-10, PAI-1 and in the coding region of  iNOS are susceptibility factors for 
the development of  GBS and whether they are related to the severity and outcome of  
the disease.
Methods
Study population 
In this study 262 GBS patients (median age at disease onset 45.5 years, range 
7-82 years, male/female ratio=1.07), who fulfilled the diagnostic criteria for GBS 
were included. Caucasian healthy blood bank donors (n=201, median age 35 years, 
range 19-60 years, male/female-ratio=0.62) served as controls. Of  the patients, 149 
had participated in one of  the Dutch trials and 30 in a national prospective study 
coordinated by the Department of  Neurology of  Erasmus MC and were clinically and 
serologically documented in detail.6 Severe (versus mild) GBS was defined as (1) an 
MRC-sumscore < 40/60 at nadir or (2) the inability to walk independently (F-score of  
3, 4 or 5). Poor outcome was defined as the inability to walk independently after six 
months of  follow-up. 
Chapter 5.2
98
Polymorphisms of  macrophage-mediators in GBS
99
DNA isolation
Isolation of  genomic DNA from EDTA anti-coagulated peripheral blood samples was 
performed with the use of  the Invisorb® MaxiBlood kit (Invitek, Berlin, Germany) 
according to the manufacturer’s instruction.
SNP detection 
The C(-1562)T polymorphism in MMP-9 was genotyped with the restriction fragment 
length polymorphism (RFLP)-technique using the restriction enzyme Sph1. Genotyping 
of  the SNPs in the promoter region of  TNF-α (C(-863)T, G(-308)A, G(-238)A), two 
SNPs in the promoter region of  IL-10 (G(-1082)A and C(-819)T), a 4G/5G insertion 
deletion polymorphism at –675 in the promoter region of  PAI-1 and one SNP in 
the coding region of  iNOS (S608L) were performed by using multiplex single base 
extension reactions. Primers and conditions for the conventional PCR-reactions and 
multiplex SBE reactions are listed in supplementary data ((E)T-1, (E)T-2).
Statistical analysis
Verification of  Hardy-Weinberg equilibrium and comparison of  genotype and 
allele-frequencies were performed using Pearson’s chi-square test or Fisher’s exact 
test when appropriate. An expectation-maximization algorithm was used to test 
for linkage disequilibrium and to compare the estimated haplotype distributions 
(http://www.mrc-bsu.cam.uk/personal/adrian/welcome.shtml). P-values < 0.05 
were considered to be statistically significant.
Results
In this study all SNPs were in Hardy-Weinberg equilibrium and the genotype 
distributions and allele frequencies did not differ between GBS patients and healthy 
controls (Table 1). The three SNPs in the promoter region of  TNF-α and the two 
SNPs in the promoter region of  IL-10 were in linkage disequilibrium (p < 0.001). 
Therefore, the haplotype distributions between GBS patients and controls could be 
compared, but this did not significantly differ between patients and controls. Since 
GBS is a heterogeneous disorder we determined whether the SNPs were associated 
with clinical or serological defined subgroups. The variant allele of  the SNP at position 
–863 of  the TNF-α gene and of  the SNP at position –1562 of  the MMP-9 gene 
were more frequently found in the severely affected GBS patients (MRC-sumscore 
< 40/60) compared to the mildly affected patients (Table 2). The genotype distribution 
of  the SNP at position –863 of  TNF-α did also differ significantly between these 
subgroups (p = 0.02), but the genotype distribution of  the SNP at position -1562 of  
the MMP-9 gene did not (p = 0.06). The haplotype distribution of  the three SNPs 
in the promoter region of  TNF-α did not significantly differ between mildly and 
severely affected patients. The variant allele of  the SNP at position –863 of  TNF-α 
was also more frequently found in the subgroup of  patients who were not able to walk 
unaided after six months compared to a large group of  patients who were able to walk 
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Table 1. Genotype distribution in Guillain-Barré patients versus healthy 
       controls. 
SNP  Guillain-Barré patients  Healthy controls
n =262 n=201
  %  %
MMP-9 C(-1562)T
CC 78.2 78.1
CT 21.4 21.9
TT   0.4      0
TNF-α C(-863)A
CC 70.6 70.6
CA 26.0 26.9
AA   3.4 2.5
TNF-α G(-308)A
GG 73.7 65.2
AG 22.1 32.8
AA   4.2   2.0
TNF-α G(-238)A
GG 87.4 86.1
AG 11.8 13.9
AA   0.8      0
IL-10 G(-1082)A
GG 27.1  26.9
AG 46.2  44.3
AA 26.7  28.9
   
IL-10 C(-819)T
CC 61.8 62.2
CT 32.4 30.8
TT   5.7   7.0
PAI-1 4G/5G
AA 31.7 27.9
GA 46.9 53.2
GG 21.4 18.9
NOS2 S608L
GG 63.7 60.2
AG 32.4 34.3
AA    3.8    5.5
No significant differences were found.
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independently after six months (Table 3). No associations were found between the 
SNPs in TNF-α, MMP-9, PAI-1, NOS and IL-10 and age, sex, antecedent infection 
and anti-ganglioside antibodies.
Discussion
Although the selected SNPs in TNF-α, MMP-9, iNOS, PAI-1 and IL-10 do not 
confer susceptibility in GBS patients, the variant alleles of  a SNP at position –863 
of  the TNF-α gene and at position –1562 of  the MMP-9 gene were associated with 
the severity of  disease based on the MRC-sumscore. Moreover, the variant allele 
of  TNF-α was also associated with poor outcome in a small subgroup of  patients. 
Therefore, these SNPs may contribute to the extent of  nerve damage mediated by 
macrophages. Previous reports showed that high serum levels of  MMP-9 as well as 
TNF-α were associated with severity of  disease.2-5 Whether these high levels of  TNF-α 
Table 2. Allele frequencies in severely versus mildly affected GBS patients.
  severity of  disease  OR (95% CI)  p-value
severely affected (n=70) mildly affected (n=78)
  % %     
TNF-α -863
C 76.4 87.2 reference 0.02
A 23.6 12.8 2.1 (1.1-3.9)
MMP-9 -1562
C 86.4 94.3 reference 0.02
T  13.6  5.7  2.6 (1.1-6.0)   
Severity of  disease was based on the Medical Research Council-sumscore at nadir ranging from tetraparalysis (score 0) 
to normal muscle strenght (score 60). Patients with a MRC-sumscore at nadir of  < 40 were defined as severely affected. 
GBS: Guillain-Barré syndrome, OR :Odds ratio, CI: confidence interval, TNF-α: tumor necrosis factor-alpha, MMP-9: 
matrix metalloproteinase 9.
Table 3. Genotype distribution of TNF-α C(-863)A polymorphism in GBS patients  
   with poor or good outcome.
  Walk independently after 6 months  OR (95% CI)  p-value
% not reached % reached 
  (n=15) (n=133)     
TNF-α -863
CC 40.0 71.4 reference 0.02
CA 46.7 25.6 3.3 (0.3-10.7)
AA  13.3   3.0  7.9 (1.2-53.9)   
The GBS functional disability score at six months was used to define the clinical outcome. Patients who were not 
able to walk independently after six months of  follow-up were defined as having a poor outcome. GBS: Guillain-
Barré syndrome, OR: Odds ratio, CI: confidence interval, TNF-α: tumor necrosis factor-alpha, MMP-9: matrix 
metalloproteinase 9.
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and MMP-9 are directly correlated to the SNPs studied is not clear. One study showed 
that the A-allele at position –863 was associated with higher TNF-α concentration 
due to an inadequate down regulation of  its production.7 In the case of  the SNP 
at position –1562 of  MMP-9, the T-allele is associated with an increased promoter 
activity that might result in higher MMP-9 levels.8 These results favor a possible 
genetic contribution of  these promoter SNPs for developing a severe form of  GBS.
Interestingly, administration of  an inhibitor of  MMP-9 and TNF-α release (BB-
1101) in a rat experimental autoimmune neuritis model for GBS prevented the 
development of  neurological deficits and conduction abnormalities or markedly 
reduced the severity of  disease.9 This finding supports the important role of  MMP-9 
and TNF-α in the pathogenesis of  GBS.
In this study we did not confirm the previously reported associations between the 
SNP at position –819 in the promoter region of  IL-10 and disease susceptibility,5 and 
between a TNF-α microsatellite marker and Campylobacter jejuni-positive GBS patients.10 
This could be caused by chance, the higher sample sizes we studied, selection of  
patients, the heterogeneity of  disease and population stratification. 
Although the association between the promoter SNPs in the MMP-9 and TNF-α 
genes and disease severity or outcome need to be confirmed in another large cohort 
of  GBS patients, it warrants further study to assess the genetic vulnerability in relation 
to severity of  disease and its therapeutic consequences.
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Abstract
Polymorphisms in genes involved in regulation of  immune homeostasis may be a 
susceptibility factor in the induction of  cross-reactive anti-ganglioside antibodies after 
infection in patients with Guillain-Barré syndrome (GBS). In this study we assessed 
whether polymorphisms in the promoter region of  Fas and FasL and sFas and sFasL 
are related to GBS or its distinct clinical or serological subgroups. We show that the 
A(-670)G SNP in the promoter region of  Fas and high levels of  sFas are associated 
with the presence of  anti-ganglioside antibodies, suggesting that Fas-FasL interaction 
is involved in the production of  cross-reactive antibodies in GBS.
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Introduction
Guillain-Barré syndrome is characterized by an acute self-limiting immune-mediated 
flaccid paralysis occurring after common infections. Autoantibodies generated by 
molecular mimicry between infectious agents and peripheral nerve structures play an 
important role in the immunopathogenesis of  GBS.1 The presence of  some of  these 
anti-ganglioside antibodies is likely to cause nerve tissue destruction in a macrophage-
mediated and complement-dependent way.2 As only 1 in approximately 1.000 to 
100.000 individuals develop GBS after a Campylobacter jejuni infection, apparently the 
occurrence of  a cross-reactive pathogenic antibody response is very rare.3 Therefore, 
genetic host factors regulating the immune response may be involved in the aberrant 
antibody response directed against self.
One of  the receptor-ligand pairs that are critically involved in the regulation of  
immune homeostasis by inducing apoptosis is Fas (CD95) and its ligand FasL (CD95L). 
Fas-FasL interactions play an important role in the elimination of  autoreactive B and 
T-cells.4, 5 We postulated that single nucleotide polymorphisms (SNPs) affecting 
the expression levels may be a susceptibility factor to develop an aberrant immune 
response leading to GBS.
Mutations in Fas (TNFRSF6) and FasL (TNFSF6) have been associated with 
lymphoproliferative syndromes and SNPs in their promoter region with several 
autoimmune disorders.6-8 These promoter SNPs, G(-1377)A and A(-670)G in the case 
of  Fas and C(-843)T in the case of  FasL, are located at transcription factor binding 
sites, thereby affecting transcriptional regulation of  these genes.9, 10 
In addition to the interactions between the membrane-bound forms of  Fas and 
FasL, soluble forms of  Fas (sFas) and FasL (sFasL) also interfere with the induction 
of  apoptosis. sFas is an alternative splice variant lacking the transmembrane domain 
of  the membrane-bound Fas molecule and it inhibits the induction of  apoptosis by 
binding to FasL.11 sFasL is cleaved by metallo-proteases from the membrane-bound 
FasL upon activation and it induces apoptosis.12 High levels of  these soluble forms 
could therefore also be involved in an aberrant immune response.
In this study, we determined whether SNPs in the promoter of  Fas and FasL are 
susceptibility factors in the development of  GBS or are related with clinical outcome 
or immunological subgroups. Furthermore, we assessed whether the serum levels of  
sFas and sFasL are related to clinical outcome or immunological subgroups.
Materials & Methods
Study population
Peripheral blood samples were obtained from 272 Caucasian GBS patients (median 
age at disease onset 46 years, range 7-82 years, male/female ratio=1.05) who had 
participated in trials or other national survey studies coordinated by the Department 
of  Neurology of  Erasmus MC.13-16 All patients fulfilled the diagnostic criteria for 
GBS.17 The protocol of  this study was reviewed and approved by the Medical Ethical 
Committee of  Erasmus MC, and all patients gave their written informed consent. Of  
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these patients, 153 had participated in one of  the Dutch GBS trials and are therefore 
prospectively documented in high detail with regard to clinical and serological 
aspects of  the disease.13, 15 The clinical and serological assessment of  this group of  
patients has been described earlier.18 In addition, clinical and serological information 
was obtained from 35 patients who had participated in a prospective study.19 In all 
patients, anti-ganglioside antibodies were determined in 180 patients (66.2%), C. jejuni 
serology in 167 patients (61.4%), Medical Research Council (MRC)-sumscore at nadir 
in 153 patients (56.3%) and the GBS disability score (F-score) at nadir in 187 patients 
(68.8%). In the remaining 84 patients, additional information was only available 
regarding sex and age.
Genomic DNA of  212 Caucasian healthy subjects (median age 35 years, range 19-60 
years, male/female-ratio=0.66) was provided by the Laboratory for Histocompatibility 
and Immunogenetics, Sanquin Bloodbank South West Region, The Netherlands. All 
healthy subjects had given written informed consent. 
Isolation of genomic DNA
Isolation of  genomic DNA from EDTA anti-coagulated peripheral blood samples was 
performed with the use of  the Invisorb MaxiBlood kit (Invitek, Berlin, Germany) 
according to the manufacturer’s instruction. At the end of  the isolation procedure, the 
DNA samples were dissolved in 0.1x TE-buffer (1mM Tris-HCl (pH 7.5) + 0.1 mM 
EDTA) and stored at -80°C. DNA samples for SNP detection were diluted in milli-Q 
to a final concentration of  10 ng/µl and stored at –20° C.
Detection of the SNPs in the promoter region of Fas and FasL
The SNPs in the promoter regions of  Fas (G(-1377)A and A(-670)G) and 
FasL(C(-843)T) were detected using the LightCycler technique (Roche Diagnostics, 
Mannheim, Germany). The SNPs located in one gene were detected in a single assay. 
The different sets of  primers and hybridization probes were designed by TibMol-
Biol (Berlin, Germany) (Table 1). The PCR-reaction and the melting curve of  all 
assays were performed in LightCycler capillaries (Roche Diagnostics) with a final 
volume of  20 µl, containing 10 ng genomic DNA, 0.5 µM of  each primer, 0.15 
µM of  each hybridisation probe, 1x LightCycler DNA Master Hybridisation Probes 
(Roche Molecular Biochemicals, Mannheim, Germany) and 3 mM MgCl
2
. The PCR 
thermocycling profile for Fas consisted of  10 min at 95°C, followed by 45 cycles of  
95 °C for 0.1 sec, 60°C for 15 sec and 72°C for 10 sec. The PCR-thermocycling profile 
for FasL was 10 min at 95°C, followed by 45 cycles of  95°C for 0.1 sec, 56°C for 15 
sec and 72°C for 15 sec. After amplification, the melting curve profile was performed 
and data were analysed using the melting curve program. To compensate for the 
interference between channels in the Fas assay, we installed a colour compensation 
set (Roche Molecular Biochemicals). In each experiment we used sequence-verified 
control donors for each genotype.
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Detection of soluble Fas and FasL in serum
We determined the levels of  sFas and sFasL using a commercially available sandwich 
ELISA kit (Diaclone Research, Besançon, France). The levels were determined in 
pre-treatment serum samples from 104 randomly selected GBS patients (20 mildly 
and 84 severely affected) and serum samples from 41 healthy individuals. In addition, 
follow-up samples from 20 severely affected GBS patients at 2 weeks and 6 months 
post-treatment were tested.
Statistical analysis 
Verification of  Hardy-Weinberg equilibrium was performed using the program of  
Ott (http://linkage.rockefeller.edu/ott/linkutil.htm#HWE). The genotype and allele-
frequencies between patients and healthy subjects were compared using Pearson’s chi-
square test. To assess the association between the haplotypes of  the Fas gene and GBS, 
several loglinear models were fitted by maximizing the log-likelihood function using the 
hapipf  program of  Mander in STATA (http://www.mrcbsu.cam.uk/personal/adrian 
/welcome.shtml). This program uses the expectation-maximization algorithm to adjust 
for unknown phase for double heterozygosity and tests for linkage disequilibrium. From 
the allelic and estimated haplotype frequencies, odds ratios were computed. Logistic 
regression was used to further analyze the observed associations. The levels of  sFas and 
sFasL in serum from patients and controls were compared using the Mann-Whitney 
U test. The Friedman test was used to compare the levels of  sFas and sFasL in related 
serum samples drawn at different time-points from individual patients. The Wilcoxon 
sign rank test was used to compare these levels in related follow-up serum samples 
at two different time points. P-values less than 0.05 were considered to be significant. 
Table 1. Primers and hybridization probes for detection of SNPs in promoter 
   region of Fas and FasL.
 primers hybridization probes
Fas GATAATACAGAGAATGCCCATATAC ACAAGGCTGGCACACCCA-Fl
G(-1377)A CCTCCTGAGGGCTTTCCA LC Red640-GTCTTCCTCATGGCACTAACAGTCTACTG-p
A(-670)G ATAGCTGGGGCTATGCGAT ATCTGTACTTTTTCATATGGTTAACTGTCC-Fl
GTCCATGTTGTGGCTGCAA LC Red705-TTCCAGAAACGTCTGTGAGC-p
FasL TGAGCCCAGGAGTTTGAG TGAAAACATTGCGAAATACAAA-Fl
C(-843)T CTCTTCCCCACACACACCTAC LC Red640-CAGCTCTGTGGGTTCCACTGGTTT-p
Fl: fluorescein, p: phosphorylated, SNP: single nucleotide polymorphism
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Results
Frequencies of SNPs in Fas and FasL genes in GBS patients versus 
controls
In this study we determined SNPs in the promoter region of  the Fas and FasL in DNA 
from 272 GBS patients and 212 healthy subjects. Since the genotype distributions 
of  all three SNPs were in Hardy-Weinberg equilibrium and the two SNPs in the 
promoter region of  Fas were also in linkage disequilibrium, we were able to compare 
the genotype, allele and haplotype frequencies between GBS patients and healthy 
controls (Table 2). In summary, the genotype and allele frequencies of  the detected 
SNPs in Fas and FasL and the haplotype frequencies of  Fas did not differ between 
GBS patients and controls.
Frequencies of SNPs in Fas and FasL genes in subgroups of GBS 
patients
GBS is a clinically defined entity, which can be subdivided based on antecedent 
infection, anti-ganglioside antibodies and neurological deficits. Therefore, we 
compared the genotype, allele- and haplotype-frequencies within clinical and 
serological subgroups of  GBS patients. We observed a significant difference in the 
genotype distribution of  the SNP at position –670 of  the Fas gene (p=0.003) and 
the Fas promoter haplotype distribution in patients with and those without anti-
ganglioside antibodies (GM1, GM2, GD1a or GQ1b) (Table 3). The frequencies of  
Table 2. Genotype and haplotype distribution in GBS patients and healthy controls.
SNP GBS patients (n=272) healthy controls (n=212)
 % %
Fas -1377
GG 76.5  80.6 
AG 22.4  18.9 
AA  1.1  0.5 
Fas -670
AA 27.9 26.4
AG 47.5 53.8
GG 24.6 19.8
Fas haplotype (-1377/-670)
GA 51.7 53.3
GG 36.0 36.8
AG 12.3  9.9 
FasL
CC 43.8 39.6
CT 42.6 49.5
TT 13.6 10.9
No significant differences were found. GBS: Guillain-Barré syndrome, SNP: single nucleotide polymorphism
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the G-allele at position –670 and the A-allele at position –1377, the GG genotype at 
position -670, the GG (-1377/-670) and AG promoter haplotype were increased in the 
patients with anti-ganglioside antibodies. 
To further evaluate the relevance of  the association between SNPs and the presence 
of  anti-ganglioside antibodies, we performed a univariate logistic regression analysis 
on the following variables: age, sex, infection (C. jejuni, CMV, EBV, or M. pneumoniae) 
and two SNPs in the Fas promoter region. The following variables showed a significant 
positive effect: infection (p=0.003), A(-670)G SNP (p=0.001) and G(-1377)A SNP 
(p=0.04) in Fas. We included these three variables in a multivariate logistic regression 
model and only infection and the SNP in Fas at position –670 showed a p-value < 
0.05. This indicates that the association between the GG genotype at –670 and the 
presence of  anti-ganglioside antibodies was independent of  the presence of  an 
antecedent infection. No associations were found between any of  the SNP and age, 
sex, antecedent infection, severity of  disease based on MRC-sumscore and GBS 
disability score and recovery.
Serum levels of sFas and sFasL 
Since soluble forms of  Fas and FasL may be involved in the dysregulation of  the 
immune response in GBS patients, we determined the levels of  sFas and sFasL in 
GBS patients and healthy controls. Levels of  sFas (median levels 134 pg/ml in GBS 
vs. 55 pg/ml in controls) and sFasL (median levels 126 pg/ml in GBS vs. 25 pg/ml in 
controls) were significantly elevated in GBS patients compared to controls (p<0.005) 
(Figure 1A and 1B). When comparing the levels of  sFas between different time-
points of  follow-up within 20 GBS patients, levels of  sFas were significantly higher 
two weeks after start of  treatment compared to pre-treatment or six months after 
Table 3.  Allele and haplotype frequencies of Fas promoter polymorphisms in 
     immunological subgroups of GBS patients.
SNP anti-ganglioside antibodies OR (95% CI) p-value
present (n=74) absent (n=106)
 % %   
Fas -1377
G-allele 81.8 89.1 reference 0.05
A-allele 18.2 10.9 1.8 (1.0-3.3)
Fas -670
A-allele 39.2 57.6 reference 0.001
G-allele 60.8 42.4 2.1 (1.4-3.2)
Fas haplotype (-1377/-670)
GA 39.2 57.5 reference 0.006
GG 42.6 31.6 2.0 (1.2-3.2)
AG 18.2 10.9 2.5 (1.3-4.8)  
Guillain-Barré patients were subdivided into those with anti-GM1, anti-GQ1b, anti-GM2 and/or anti-GD1a 
antibodies and those without these anti-ganglioside antibodies.
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Figure 1.  Levels of sFas and sFasL in serum from GBS patients in relation to the 
presence of anti-ganglioside antibodies and severity.
Levels of  soluble Fas (A) and FasL (B) in serum from GBS patients (n=104) versus controls (n=41). In 
panel C and D, patients were subdivided into those with anti-GM1, anti-GQ1b, anti-GM2 or anti-GD1a 
antibodies (titre ≥ 100, n=33) and those without these antibodies (titre <100, n=51). In panel E and F, 
patients were subdivided based on the GBS disability score (F-score). Patients who were not able to walk 
independently (F-score ≥ 3) were defined as severely affected patients (n=78) and those who were able 
to walk independently (F-score ≤2) as mildly affected (n=20). The thick black line represents the median 
level of  sFas and sFasL per group. 
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treatment (p=0.02); median levels pre-treatment were 116.5 pg/ml, 2 weeks post-
treatment 429 pg/ml and six months post-treatment 104 pg/ml. The levels of  sFasL 
did not change significantly in GBS patients during follow-up. 
In subgroups of  patients, levels of  sFas tended to be elevated in the patients 
with anti-ganglioside antibodies (median level 195 pg/ml) compared with patients 
without these antibodies (median level 97 pg/ml; p=0.056; Figure 1C), but fell short 
of  reaching significance. Levels of  sFasL were not significantly different in these 
subgroups (Figure 1D). The levels of  sFasL were significantly higher in mildly affected 
patients (median level 181.5 pg/ml vs. 101 pg/ml; p=0.01). There was no association 
between disease severity and sFas levels (Figure 1E and 1F).
The frequencies of  the different genotypes within the group of  randomly selected 
patients (n=104) at position –670 were 25.6% GG, 50.0% AG and 24.4% AA, at 
position –1377 32.6% AG and 67.4% GG and at position –843 of  FasL 14.0% TT, 
46.5% CT and 39.5% CC, which do not differ from the total group of  patients. Since 
the soluble levels of  Fas and FasL are not correlated with the SNPs we do not show 
the genotypes in figure 1. 
Discussion
Fas-FasL interactions are crucial in the elimination of  autoreactive B and T cells, and 
several other celltypes. SNPs in genes coding for these immunoregulatory molecules 
are associated with several antibody related autoimmune diseases, such as Sjögren’s 
syndrome and systemic lupus erythematosus.6-8 In this study we showed that these 
SNPs are not a general susceptibility factor in GBS. However, SNPs in the promoter 
region of  Fas, in particular the SNP at position –670, and sFas were associated with the 
presence of  anti-ganglioside antibodies in GBS patients. These SNPs as well as sFas 
may inhibit apoptosis via different mechanisms, which are discussed below.
The subgroup of  patients with anti-ganglioside antibodies was defined by the 
presence of  at least one of  the most commonly found anti-ganglioside antibodies 
in GBS: anti-GM1, -GM2, -GD1a and -GQ1b antibodies. Within these subgroup of  
patient higher frequencies of  the G-allele and GG genotype at position –670, the A-
allele at position -1377 and the GG(-1377/-670) and AG promoter haplotypes of  Fas 
were found compared to those patients without these antibodies. The SNPs at positions 
-670 and -1377 are both located at transcription factor binding sites and likely regulate 
the transcriptional activity of  the Fas gene. The G-allele at position –670 is associated 
with a lower transcriptional activity compared to the A-allele.20 In the case of  the SNP 
at position -1377, the A-allele is associated with a reduced binding of  the transcription 
factor and therefore postulated to result in reduced Fas expression.21 The increased 
frequencies of  the promoter haplotypes associated with lower Fas expression might 
indicate a diminished induction of  apoptosis in B-cells in these GBS patients, which 
may contribute to the production of  cross-reactive antibodies after infection. 
GBS has been reported in two of  23 patients with the very rare autoimmune 
lymphoproliferative syndrome (ALPS), which is caused by mutations in Fas or 
Chapter 6
114
Apoptosis
115
FasL.22-24Autoimmune disorders characterized by the presence of  autoantibodies 
frequently occur in patients with ALPS. Most likely this association is due to impaired 
apoptosis caused by the mutations in Fas and FasL22 As far as we know no SNPs in 
the coding regions resulting in an amino acid substitution have been reported in Fas 
and FasL. The effects of  the promoter SNPs in the current study will be small and 
less detrimental than the mutations in the Fas or FasL in ALPS. Nevertheless these 
SNPs might be one of  the genetic susceptibility factors involved in the production of  
autoantibodies. 
In this study levels of  sFas and sFasL were increased in pre-treatment serum 
samples from GBS patients compared to healthy controls. These increased levels of  
sFas and sFasL most likely reflect disease activity as has been reported for several 
immune-mediated disorders.25-27 The initial increase of  sFas in GBS patients is not 
likely to be due to their treatment with plasma exchange, intravenous immunoglobulins 
(IVIg) or IVIg plus methylprednisolone, since none of  these affect the levels of  
sFas.28, 29 Since sFas inhibits apoptosis by binding to membrane-bound FasL, high 
levels of  this molecule in the group of  patients with anti-ganglioside antibodies 
might act in conjunction with the observed higher frequency of  the Fas promoter 
haplotype associated with lower expression of  Fas. Both factors might be associated 
with diminished apoptosis of  B-cells that are responsible for the production of  these 
antibodies. Reduced apoptosis of  antigen presenting cells and T cells, which may also 
be involved in the anti-ganglioside antibody production, may also have contributed to 
the aberrant immune response in GBS.
We also observed higher levels of  sFasL in the mildly affected group of  patients, 
who were still able to walk independently at nadir. Besides a role in eliminating of  
autoreactive B- and T-cells, Fas-FasL interactions may also cause tissue destruction 
or be involved in axonal regeneration. Schwann cells express high levels of  both 
Fas and FasL.30 This Fas expression may play a role in apoptosis of  Schwann cells. 
On the other hand FasL expression on Schwann cells may induce apoptosis of  Fas-
bearing invading cells. Soluble FasL may also interfere with these Fas-bearing cells 
and favour the elimination of  invading cells. In addition, sFasL may promote axonal 
regeneration.31 These anti-inflammatory and recovery effects of  sFasL may possibly 
explain the observed high sFasL in mildly affected GBS patients compared to severely 
affected GBS patients.  
In conclusion, SNPs in the promoter region of  Fas and FasL are not a general 
susceptibility factor for GBS. Subgroup analysis showed that the GG genotype at 
position –670 and the GG and AG promoter haplotypes of  Fas and high levels of  
sFas are associated with the presence of  anti-ganglioside antibodies in GBS patients, 
suggesting that Fas-FasL interactions are involved in the induction of  a cross-reactive 
immune response after infection. The associations at genomic level could theoretically 
be merely due to multiple-testing bias and hence require confirmation in another well-
documented and large group of  Caucasian GBS patients. Further functional studies 
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are warranted to elucidate the role of  these SNPs and sFas in the immunopathogenesis 
of  GBS.
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Guillain-Barré syndrome is a rare immune-mediated polyneuropathy that occurs 
after common types of  infection. Several lines of  evidence show that this antecedent 
infection triggers the induction of  anti-ganglioside antibodies and onset of  GBS.1, 2 
However, since only 1 per 1000 infected persons develops GBS after such a common 
infection3, host factors are also likely to be involved. This thesis focuses on the 
contribution of  genetic factors in patients with GBS. Two different approaches were 
used to assess whether there is a genetic susceptibility for the development of  GBS or 
for its specific clinical or serological subgroups, including (1) a search for a substantial 
number of  families with GBS and (2) population-based genetic association studies. 
Several SNPs in candidate genes were selected for these studies based on their central 
role in the immune response and their reported effect on protein levels or protein 
function. The molecules and their interactions are schematically represented in 
Figure 1. In this section, the methodological issues of  the studies performed will 
be discussed first. Hereafter, a short overview of  the results will be presented and 
discussed. Finally, some future directions will be put forward.
Methodological issues
GBS cohort 
The population-based genetic association studies were performed in one of  the worlds 
largest group of  well-documented GBS patients. The majority of  these patients had 
participated in one of  the Dutch treatment trials or surveys and were therefore 
documented in high detail with regard to antecedent infections, anti-ganglioside 
antibodies and clinical characteristics at standardized time points during a six-month 
follow-up. 
Since we have detailed clinical and serological information, this enabled us to 
perform subgroup analyses. These subgroup analyses are of  importance as the 
underlying immunological mechanisms might be different per antecedent infection 
and therefore also the genes that confer susceptibility. The patients included in the 
genetic studies did not differ from the whole group of  GBS patients with respect to 
the clinical and serological characteristics. Most of  the patients participated in one of  
the trials and were severely affected based on the functional disability score (F-score 
≥ 3) as this was a primary inclusion criterion.4, 5 Therefore, the number of  patients 
who were mildly affected is relatively low in these genetic studies. Another way of  
defining severity of  disease is based on the MRC-sumscore (ranging from 0-60) by 
using its median value as cut-off  point: patients with an MRC-sumscore < 40 at 
nadir are defined as severely affected GBS patients.6 In the genetic association studies 
both ways of  defining severity of  disease were used to assess whether SNPs were 
associated with disease severity. Performing subgroup analysis based on serological 
characteristics is limited by the sensitivity and specificity of  the assays used for the 
detection of  infections and anti-ganglioside antibodies. In addition patients with 
negative serology may have had other types of  infections or antibodies directed 
against other gangliosides or ganglioside complexes as has been recently reported.7 
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In this view, subgroup analysis relies on the possibility to define subgroups based on 
clinical, infectious and immunological characteristics, which were largely present in our 
cohort of  patients.
������ �����������
�������
����������
�����
��
��
��
�����
��
��
��
��
�
������
�����
��
�����
���
���
��������
�����
����
����
�
�
��
�
�
��
����
������
���
�����
�
�
��
���
������
����
�
��
��
�
�
��
��
�
�
��
�
�
�
�
�
�
�
�
�
�
��������
���
��
���
��
��
����
�
�
��
���
�����������
�����������
�
�
Figure 1.
The pattern recognition receptors CD14 and Toll-like receptor 4 (TLR-4) are involved in the recognition 
of  LPS and in inducing the synthesis of  pro-inflammatory cytokines and co-stimulatory molecules 
favoring an adaptive immune response.41, 42 The polymorphic HLA-system10 and costimulatory molecules 
(CD28, CD86, CTLA4, CD40, CD40L and ICAM1) provide the first and secondary signals to activate 
naive T-cells and B-cells.28 Activation of  the complement system by mannose-binding lectin (MBL), 
the release of  tumor necrosis factor-alpha (TNF-α), matrix metalloproteinse-9 (MMP-9), nitric oxide 
(NO), plasminogen-activator inhibitor 1 (PAI-1) and Fc receptor (FcR)-mediated antibody dependent 
cell-cytotoxicity are likely to contribute to the extent of  nerve damage in GBS patients.18, 19, 43 Fas and its 
ligand (FasL) play an important role in eliminating autoreactive T and B-cells (not shown).
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Control group 
Two hundred and twelve Dutch healthy blood bank donors were used as controls in 
the population-based genetic association studies. GBS patients as well as the healthy 
subjects were all Caucasians. The HLA-allele frequencies of  the control group were 
compared with the frequencies of  a large Dutch cohort of  healthy controls (n=2440) 
and proved to be representative for the general Dutch Caucasian population.8 The 
distribution of  the other polymorphism studied did also not differ between our 
control group and other Caucasian control groups, indicating that the control group 
was representative for Caucasian populations.
The controls had not suffered from GBS in the past, but it cannot be excluded 
that they will develop GBS in the future. Based on the lifetime risk (approximately 1:
1000) to develop GBS and the number of  controls (n=212), however, this chance is 
very small and will not influence the conclusions based on the comparisons between 
GBS and controls. 
No data are available on the infection status of  these controls. To identify genetic 
host factors that determine the susceptibility to develop GBS after a specific type of  
infection our cohort of  patients preferentially should have been compared with a 
group of  infection matched controls. Based on the high incidence of  C. jejuni infection 
and CMV-infection in the general population, the majority of  controls, however, are 
expected to have had one of  these infections at any point during life. 
Genotyping methods 
A highly sensitive and specific PCR-based method, the LightCycler, was used to 
determine most of  the SNPs in patients and controls.9 As an internal quality control 
for this assay, sequence verified controls of  each genotype per SNP were used. DNA 
was of  high quality since all samples could be determined by using the LightCycler 
technique. When it was impossible to develop appropriate hybridization probes to 
detect a SNP, the LightCycler method could not be used. This was the case for the 
C(-1562)T polymorphism in the MMP9 gene and the C(-260)T polymorphism in the 
CD14 gene. In these cases, the restriction fragment length polymorphism analysis was 
used. Sequence verified controls with an additional restriction site were also used in 
these assays as internal quality controls. 
Population-based genetic study design 
Population-based genetic association studies are a way to study the contribution 
of  genetic factors in the development or severity of  a disease. One major issue in 
reporting the results of  these kinds of  studies generally is the inability to replicate 
many of  these results. Population stratification, misclassification of  outcome and 
allelic heterogeneity has been suggested as underlying factors, but publication bias, 
failure to attribute results to chance and inadequate sample sizes seem to be the most 
important factors underlying inability to replicate. 
Publication bias. Negative studies are underreported in international journals. 
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Systematic reviews of  published results are therefore skewed to positive studies, and 
conclusions based on these results may be too optimistic.
Multiple testing. One of  the major reasons for difficulties in replication is the failure 
to exclude chance. Hundreds of  genes are possible candidate genes and several SNPs 
will be screened in one specific disorder. In addition subgroup-analysis or haplotype-
analyses will be performed after initial tests of  association that did not reach 
significance, thereby increasing the chance of  finding an association.10 For example, in 
this thesis we performed analysis on 18 different subgroups per SNP. The probability 
of  finding at least one significant association per SNP studied with a p-value <0.05 in 
one of  these subgroups that is based on chance alone is 60%. One strategy to reduce 
false positive associations is to apply corrections for multiple testing. A classic approach 
is to adjust the significance level by applying the Bonferroni correction (p-value 
divided by subgroups 0.05/18= 0.0027), which will ensure that when null hypotheses 
are true, the probability of  obtaining at least one result more extreme than threshold 
will be about 5%. However, this situation is an oversimplification since the probability 
of  a given association being true or false is not only dependent on significance level, 
but also on number of  hypotheses being tested for which the null hypothesis is true. 
Significance thresholds of  5x10-5 have been proposed for association studies to adjust 
for 1000 SNPs being worldwide tested.10 However, by using such stringent p-values, 
assessing the contribution of  a SNP in the development or severity of  a disease will be 
very hard since the contribution of  an individual SNP is rather small. To increase the 
prior probability of  a true association we selected polymorphisms in genes encoding 
molecules that are likely to be involved in the pathogenesis of  GBS and which have 
a functional effect at protein level. In the case of  MBL2 we additionally performed 
functional assays to support the relation at genetic level. Another way to prove that 
the observed association is correctly is to confirm the association in a larger cohort of  
GBS patients and controls, which is one of  our recommendations.
Insufficient power. In complex disorders the effect of  an individual SNP will be small, 
since several SNPs and other factors will determine disease susceptibility. To be able 
to detect such a small effect, a large cohort of  patients and controls is required. In 
this study one of  the largest group of  GBS patients was studied. By comparing this 
group of  patients with 212 healthy controls, a standardized difference of  0.26 could 
be detected at a significance level of  5% and a power of  80%. For example, in the 
case of  an allele frequency of  30% in the healthy controls, an odds-ratio of  1.4 could 
have been detected. When applying correction for the multiple tests performed larger 
sample sizes would be required to detect such a small difference. 
Genetic host factors in Guillain-Barré syndrome
In Chapter 2 of  this thesis 12 Dutch families are presented in which two or more 
GBS patients were identified. We observed a slightly more frequent occurrence of  
GBS within siblings, but this did not reach significance due to inadequate power of  
the study. We observed an earlier onset of  GBS in successive generations, which 
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retrospectively could also be observed in other family-reports. Moreover, one of  the 
patients had four times GBS. Collectively, these results suggest a genetic contribution 
to the pathogenesis of  GBS. Larger numbers of  families are required to establish 
familial aggregation in GBS. The results of  the population-based genetic association 
studies are described in Chapters 3-6 and the main findings are listed in Table 1. 
Do genetic variants confer susceptibility to GBS?
In this thesis none of  the immunogenetic polymorphisms studied conferred disease 
susceptibility in GBS patients upon infection. Three previous reports showed that 
SNPs in the immune-response genes encoding IL-10, Fcγ receptors and the kappa 
light chains of  immunoglobulins (KM genes) conferred disease susceptibility.11-13 
However, in case of  IL-10 the results could not be replicated in our large cohort 
of  GBS patients (Chapter 5.2). In the case of  the Fc-receptors, a meta-analysis of  
a Dutch, English and Norwegian GBS population did not confirm the association 
between the polymorphisms and disease susceptibility.14 
Although most of  these results do not support a role of  SNPs in conferring disease 
susceptibility, the rare occurrence of  GBS after common types of  infection is still a 
strong argument favoring a genetic contribution to develop GBS. However, identifying 
genetic variants that contributes to disease susceptibility might be a daunting task, due 
to the evident role of  common antecedent infections and pathogen-related factors, the 
small effect of  each individual SNP, the large number of  SNPs involved, the gene-gene 
interactions and gene-environment interactions that have to be taken into account. 
Do genetic variants contribute to the production of cross-reactive 
antibodies? 
The presence of  the cross-reactive anti-ganglioside antibodies in serum from GBS 
patients is one of  the immunological hallmarks in GBS patients. These antibodies are 
initially evoked against structures present on the outer membrane of  a pathogen and 
cross-react with gangliosides that are present on peripheral or cranial nerves.1 Genes 
encoding proteins involved in antigen presentation, costimulation and life and death 
of  B-cells are good candidate genes to assess whether the production of  these cross-
reactive antibodies is genetically determined. In this thesis, associations between (i) the 
Fas haplotype associated with a lower Fas expression15, 16 (Chapter 6), (ii) the variant 
allele of  CD40 at position –1 that might affect the expression levels of  
CD4017 (Chapter 4.2) and the production of  anti-ganglioside antibodies are reported. 
The presence of  the Fas promoter haplotype associated with a lower expression of  Fas 
might results in a diminished induction of  apoptosis in B-cell, which may contribute to 
the production of  cross-reactive antibodies after infection. In addition, CD40-CD40L 
interactions are essential for activation, differentiation and isotype switching of  the 
B-cell and also for rescuing the B-cell from apoptosis.18 Overexpression of  CD40 and 
CD40L has been suggested to play an important role in humoral autoimmunity due 
to excessive B-cell activation, class switching and autoantibody production.19, 20 So, 
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Fas-FasL and CD40-CD40L interactions are both involved in the decision whether 
B-cells survive selection in the germinal centres.19 Collectively, our results suggest that 
there are, besides the pathogen-related factors, genetic factors that partially determine 
whether a person produces cross-reactive antibodies.
Do genetic variants contribute to the severity of GBS?
The severity of  GBS depends on the extent of  damage of  peripheral or cranial nerve 
fibres. SNPs may also influence this damage with respect to (i) the extent of  immune 
activation, (ii) the production of  antibodies, and (iii) complement and macrophage-
mediated nerve damage. 
In this thesis SNPs in the MBL2, TNF-α and MMP-9 genes, encoding molecules 
that are all involved in complement and macrophage-mediated nerve damage, were 
associated with the severity of  disease based on the MRC-sumscore at nadir. The 
MRC-sumscore assesses the muscle strength in 6 bilateral muscle groups, ranging 
from 60 (normal) to 0 (tetraparalysis).21 This sumscore reflects the extent of  motor 
fiber damage. The frequency of  the MBL2 haplotype associated with the highest 
MBL concentration and complex activity (HYA haplotype) was increased in GBS 
patients with a severe weakness compared with patients who were mildly affected. 
This association is further supported at serological and functional level; high MBL 
concentration and MBL complex activity are also associated with severe weakness. The 
correlation between high MBL concentration and complex activity, co-determined by 
the HYA haplotype, and severe weakness may indicate that patients only develop a 
severe form of  GBS when a certain threshold level of  MBL is present 
(Chapter 5.1). As GBS is a very complex and heterogeneous disorder other factors 
inhibiting the complement-factors like decay accelerating factor (DAF/CD55) and 
CD59, will probably co-determine the extent of  nerve damage. 
The variant alleles of  SNPs at position –863 of  the TNF-α gene and at position 
–1562 of  the MMP-9 gene, both probably resulting in higher levels of  the encoded 
molecules are also associated with severe weakness (Chapter 5.2). Interestingly, 
previous reports showed that high serum levels of  MMP-9 as well as TNF-α were 
associated with severity of  disease.22, 23 In addition administration of  an inhibitor of  
MMP-9 and TNF-α release (BB-1101) in a rat experimental autoimmune neuritis 
model for GBS prevented the development of  neurological deficits and conduction 
abnormalities or markedly reduced the severity of  disease.24
FcR polymorphisms have also been reported to be associated with severity of  
disease based on the functional disability score or an expanded clinical grading scale 
and in a meta-analysis.12, 14, 25 In the F-score also the extent of  sensory nerve damage is 
important. We observed an association between a promoter haplotype in the CTLA4 
gene and a mild course of  GBS based on this F-score (F-score ≤ 2; Chapter 4.2). 
This promoter haplotype has been reported to be associated with a higher expression 
of  CTLA-4.26, 27 CTLA-4 down-regulates the activation of  T-cells, suggesting that a 
higher expression of  this molecule might favors a mild course of  disease.28 Since our 
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group of  mildly affected GBS patients based on the F-score is small (n=14), a larger 
group of  mildly affected patients is required to draw any conclusion.
Collectively, these results favor a possible genetic contribution of  SNPs in 
developing a severe form of  GBS.
Do genetic variants contribute to the outcome of GBS?
Data obtained from large randomized clinical trials have indicated some prognostic 
factors for predicting poor outcome:
a) older age (> 50 years)
b) low MRC-sumscore at entry
c) high F-score at entry or nadir 
d) rapid onset of  muscle weakness (time between onset and day of     
 randomization < 4 days)
e) preceding (C. jejuni) enteritis
f) recent CMV infection
g) low or absent muscle action potential amplitudes6, 29
Genetic variants in genes encoding molecules involved in the extent of  nerve damage 
are also likely to be of  prognostic value. Indeed, the variant allele at position -863 
of  TNF-α gene is also associated with a poor outcome, which was defined as not 
being able to walk unaided after six months of  follow-up. No other studies assessed 
whether SNPs are associated with poor outcome. Our result encourages further 
searches of  candidate genes in determining the outcome of  GBS patients. To assess 
the contribution of  SNPs in determining outcome, larger group of  GBS patients with 
a poor outcome based on the F-score at six months are required. 
Genetic variants contribute to GBS; a summary
The results described in this thesis favor a contribution of  genetic factors in GBS, 
since:
a) at least 12 families with GBS in The Netherlands are present and GBS    
 occurred a slightly more frequent in siblings (Chapter 2).
b) SNPs in genes encoding molecules involved in life and death of  B-cells    
 are associated with the presence of  cross-reactive antibodies in serum of  GBS   
 patients (Chapter 4.2 and Chapter 6).
c) SNPs in genes encoding molecules involved in nerve damage are associated with  
 the severity of  disease and outcome (Chapter 5.1 and Chapter 5.2). 
One of  these genetic associations (the MBL2 HYA haplotype and severe weakness) 
has been supported by functional assays, which strengthen its genetic contribution in 
the pathogenesis of  GBS. The other reported associations have to be confirmed in 
another large GBS cohort to exclude the possibility that these associations are based 
on chance alone. To further assess the effects of  these SNPs in the production of  
antibodies, disease severity and outcome, functional assays are warranted.
The aberrant immune response in GBS is initially evoked by different antecedent 
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infections, which might be recognized by different pattern recognition receptors 
present on immune cells, thereby activating different downstream pathways leading 
eventually to a cross-reactive antibody response. Since this complexity in the afferent 
phase of  the immune response in which infections play an important role and the 
effect of  individual genes will be small and might be different per infection, unravelling 
genetic factors involved in this process will be hard or even inconceivable. This 
conclusion might be daunting, however, genetic screening may be useful in predicting 
the severity or outcome in GBS patients, which will deal with great uncertainties of  
patients, their relatives and physicians as well. The severity of  disease and outcome is 
determined by several factors (described above), including the administered treatment. 
In this thesis only immune-response genes have been studied to assess whether genetic 
factors are related to disease severity or outcome. However, other genes might also be 
involved in conferring disease severity and predicting outcome. Some candidate genes 
are suggested below.
Candidate genes to assess a genetic contribution to disease 
severity and outcome
Genes encoding Schwann-cell related molecules 
Peripheral myelin protein 22 (PMP22), myelin protein zero (P0) and connexin 32 
(CX32) are Schwann-cell related molecules, which are involved in the promotion 
of  myelin formation and the maintenance and compaction of  myelin. Mutations in 
the genes encoding these molecules are associated with hereditary neuropathies.30 
Polymorphisms in these genes might be partially determining the extent of  nerve 
damage in GBS patients and could be therefore of  prognostic value. 
Genes encoding neurotrophic factors 
Neurotrophic factors, like glia-derived neurotrophic factor (GDNF), nerve growth 
factor (NGF) and insulin-like growth factor (IGF) and their receptors play an important 
role in protecting and preventing motor-neuron death and in the regeneration of  
nerves after injury.31, 32 Polymorphisms in these genes that affect the levels and/or 
functions of  these factors might be genetic factors related to the severity of  GBS. 
Pharmocogenetics 
The outcome of  GBS patients is partly determined by the therapy administered. SNPs 
in genes influencing interindividual variations in drug response might partly determine 
the effect of  a treatment and thereby the outcome. In GBS patients the response 
to IVIg may be influenced by Fcγ-receptor polymorphisms33 and the response to 
methylprednisolone might be less effective when the human glucorticoid 
receptor β variant is present. This variant allele is associated with a reduced sensitivity 
to glucocorticoids.34 Other drug-response genes might also be involved. Recently, a set 
of  tagging genes involved in absorption, distribution, metabolism and excretion of  
drugs has been identified, which might be useful in identifying the patients most likely 
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to respond positively to a certain medication. In addition, drugs likely to give negative 
side effects can be avoided.35
Ways to study the genetic contribution of GBS in future
It will be a major challenge to find genes or pattern of  genes predicting the outcome 
of  GBS at onset of  disease, as this might have consequences to decide whether 
additional therapy is required. In this thesis we assessed whether individual SNPs 
were associated with disease severity, anti-ganglioside antibody production, disease 
severity and outcome. Since several SNPs and epistasis are likely to contribute to the 
pathogenesis of  GBS, assessing the effect of  only one SNP a time might not detect the 
contribution of  this SNP to the pathogenesis of  GBS. Recently, several appropriate 
methods have been developed which could be applied to our dataset to capture the 
contribution from multiple susceptibility loci located on different chromosomes.36
In future, a large European or even worldwide collaborative study is required to 
collect a DNA database from patients and controls that is large enough to deal with 
more stringent p-values to ascertain that the ratio of  true positive and false positive 
associations will be 20:1.10 For example, in the case we want to detect an odds ratio of  
1.15 at p=5x 10-5 by 80% power and an allele frequency of  30% in healthy controls, 
4800 cases and 4800 controls would be required. A problem that might arise from a 
worldwide collaborative study is population stratification. However, a few strategies 
can be applied to overcome population stratification: i) carefully matching of  cases 
and controls by demographic background, ii) screening for anonymous genetic 
markers (null loci) to detect population substructures and when these are present, 
association of  the SNP with disease should be performed in each subpopulation37 and 
iii) performing a transmission disequilibrium test (TDT) in family-based association 
studies.38 
In this collaborative study it is of  great importance to include GBS patients only 
as they are well documented with regard to antecedent infections, anti-ganglioside 
antibodies as well as clinical characteristics enabling the comparison of  homogeneous 
groups of  GBS patients. 
In this thesis individual SNPs in candidate genes were determined in single assays. 
Other approaches are to assess tag SNPs within one gene, which is a reduced set of  
SNPs that can provide information about the presence of  other alleles at different 
loci. This approach is likely to result in gain of  efficiency and lower costs and is 
suitable in the case of  common disease-common variant approach.39 However, in 
the case of  searching for rare alleles a considerable loss in power of  association 
test is likely to be the result. Another approach is to perform genome-wide studies 
by using commercially available micro-array chips containing up to 100.000 SNPs. 
These chips contain SNPs with known and unknown effects. The main advantages 
of  these SNP-chips are the high-throughput, low costs per SNP and increased power. 
A main disadvantage of  these SNPs is the increased number of  SNPs being tested 
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irrespectively of  whether the SNPs are good candidate genes or not for an effect on 
disease risk, thereby reducing the prior probability of  a true association.40
In conclusion
The results described in this thesis are based on one of  world largest cohorts of  
well-documented GBS patients and favor some contribution of  genetic factors in 
the pathogenesis of  GBS. Although genetic factors could be involved in disease 
susceptibility, most evidence for a genetic contribution has been found in relation to 
disease severity. Identifying general genetic factors related to disease susceptibility of  
GBS seems rather a daunting task, since susceptibility genes may be so numerous, their 
interactions so divers and dependent on the type of  antecedent infection. Based on 
the results described in this thesis, studying SNPs in relation to severity of  disease or 
outcome is promising. An European or worldwide collaborative study would enable 
us to collect an extended cohort of  well-documented GBS patients and to assess the 
contribution of  SNPs in determining disease severity and outcome, which in turn 
might give valuable information to direction and intensity of  treatment required.
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Summary
Guillain-Barré syndrome is a rare but potentially severe disease in which the peripheral 
nerves are affected by the immune system. Signaling from brain to muscles is impaired 
by the immune attack directed to the peripheral nerves, resulting in muscle weakness 
ranging from a mild decrease of  muscle strength to a complete paralysis. 
GBS is often preceded by an infection with a bacterium (Campylobacter jejuni, 
Mycoplasma pneumoniae, or Haemophilus influenzae) or a virus (cytomegalovirus, Epstein-
Barr virus). These infections commonly occur in the general population. Our immune 
system is activated to eradicate these invading pathogens. However, in GBS the 
immune response is not only directed to the pathogen, but also to the peripheral 
nerve tissue (cross-reactive immune response). Previous reports showed that the 
bacterium or virus bears structures on its surface that resemble structures present on 
the peripheral nerves (molecular mimicry). This molecular mimicry is probably crucial 
for the induction of  anti-ganglioside antibodies. However, the production of  these 
antibodies is also dependent of  other factors. 
This thesis focuses on the contribution of  genetic host factors in GBS. Two 
different approaches were used to assess the contribution of  these genetic factors: 1. 
To identify families in which two or more members are affected. 2. To perform genetic 
population-based association studies comparing large groups of  unrelated GBS 
patients and healthy controls to assess whether candidate immune response genes are 
susceptibility factors for conferring GBS or associated with clinical and serological 
subgroups of  GBS.
In Chapter 2, 12 Dutch families in which more than one case of  GBS is present 
are described. The number of  reported families is insufficient to prove that there 
is a familial occurrence of  GBS. A genetic susceptibility is suggested by the slightly 
more frequent occurrence of  GBS within siblings, the observed earlier onset of  
GBS in successive generations and the single patient who developed GBS at four 
different occasions. Chapters 3-6 describe the results of  the population-based genetic 
association studies performed in one of  world largest group of  well-documented 
GBS patients (n=272) and a group of  healthy Dutch blood bank donors (n=212) as 
controls. Polymorphisms in several immune-response genes have been studied (listed 
in Appendix 2). In Chapter 3, we assessed whether known functional polymorphisms 
in the LPS receptors CD14 and Toll-like receptor 4 (TLR4) are associated with an 
increased susceptibility for GBS or C. jejuni related clinical and serological features. 
The C(-260)T polymorphisms in CD14 and the A(+896)G and C(+1196) in TLR4 
did not confer disease susceptibility and were not associated with a preceding C. jejuni 
infection or its related clinical or serological subgroups, suggesting that these SNPs are 
not genetic host factors. 
The distribution of  the HLA-DRB1 and HLA-DQB1 antigens, involved in antigen 
presentation for B-cell responses, were compared between GBS patients and healthy 
controls in Chapter 4.1. No differences in distribution between these two groups 
were observed. However, the frequency of  the HLA-DR1 antigen was increased in 
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the group of  patients who required artificial respiration compared to those who did 
not. We reviewed all HLA-studies performed in GBS patients and conclude that the 
polymorphic HLA system is not a general susceptibility factor to develop GBS. Given 
the association between HLA-DR1 and artificial ventilation in GBS patients, the 
HLA-system might play a modulatory role in certain subgroups of  GBS patients.
Besides the presentation of  antigens to naive lymphocytes, signals provided via 
co-stimulatory molecules are also required to activate these cells. In Chapter 4.2 
we assessed whether immunogenetic polymorphisms in the genes encoding these 
molecules conferred disease susceptibility or are related to specific subgroups of  GBS 
patients. The T-allele at position –318 of  the promoter region of  CTLA4 and its T-
318A+49 haplotype, probably resulting in a higher expression of  CTLA-4 (which exerts 
an inhibitory role on activated T-cells) were associated with a mild form of  disease 
(F-score ≤ 2). The T-allele at position –1 of  CD40, a molecule involved in B-cell 
activation, was associated with the presence of  anti-ganglioside antibodies, suggesting 
a role of  this SNP in the production of  anti-ganglioside antibodies.
The studies described in Chapter 5 focus on SNPs in genes encoding molecules 
involved in complement and macrophage mediated nerve damage. Mannose-binding 
lectin recognizes sugar groups on pathogens, thereby activating the lectin pathway 
of  the complement system and facilitating phagocytosis. In Chapter 5.1 we showed 
that the frequency of  the HYA haplotype, which is associated with highest MBL 
concentration, was increased in GBS patients compared to controls, especially in 
patients who had severe weakness. Highest MBL concentration and MBL complex 
activity were also associated with severe weakness, suggesting that high levels of  
functional MBL predispose for developing a severe form of  GBS.
In Chapter 5.2 it is shown that the variant alleles of  a SNP in the promoter region 
of  TNF-α (-863) and a SNP in the promoter region of  MMP-9 (-1562) were also 
associated with severe weakness. These molecules are released by macrophages and 
may be involved in blood-nerve barrier breaching and aggravating tissue damage. 
Fas-FasL interactions play an important role in inducing apoptosis in the Fas-
bearing cells, thereby eliminating autoreactive T- and B-cells. The frequency of  
a promoter haplotype in the Fas gene associated with lowest Fas expression was 
increased in patients with detectable levels of  anti-ganglioside antibodies in their serum 
(Chapter 6). Soluble levels of  Fas that inhibits apoptosis by binding to membrane-
bound FasL, were also higher in patients with detectable levels of  anti-ganglioside 
antibodies. These results suggest that factors associated with a diminished apoptosis 
at least partly determine the induction of  cross-reactive antibodies.
Finally, Chapter 7 provides a discussion of  the results and their contribution to 
understanding disease susceptibility, anti-ganglioside production, severity and outcome 
of  GBS. Based on the results in this thesis, we conclude that there is some evidence 
that genetic factors play a role in the pathogenesis of  GBS. Most of  the reported 
associations were found between SNPs and disease severity or outcome and not the 
onset of  GBS. These results are important for a better understanding of  the factors 
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that are involved in determining severity of  disease. Future research could focus on 
other candidate genes involved in determining disease severity, which in turn might 
give valuable information to the direction and intensity of  treatment required.
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Het Guillain-Barré syndroom (GBS) is een zeldzame, maar potentieel ernstige ziekte 
waarbij de perifere zenuwen (door het eigen afweersysteem) worden aangetast. Door 
de aantasting van de zenuw worden de signalen vanuit de hersenen minder goed of  
helemaal niet meer doorgegeven aan de spieren, waardoor de patiënten met GBS 
minder spierkracht hebben of  zelfs totaal verlamd kunnen zijn. 
De ziekte wordt vaak voorafgegaan door een infectie met een bacterie (Campylobacter 
jejuni, Mycoplasma pneumoniae, Haemophilus influenzae) of  een virus (Cytomegalovirus, 
Epstein-Barr virus). Deze infecties komen veel voor in de algemene bevolking. Deze 
infecties worden door ons lichaam bestreden door een afweerreactie in gang te zetten 
met als doel de bacterie of  virus te doden. Bij GBS patiënten is deze afweerreactie niet 
alleen gericht tegen de bacterie of  het virus, maar ook tegen het eigen zenuwweefsel 
(kruisreagerende afweerreactie). Eerder onderzoek heeft aangetoond dat de bacterie 
of  het virus bepaalde structuren op het oppervlak draagt die lijken op structuren die 
voorkomen op ons zenuwweefsel (moleculaire mimicry). 
Deze moleculaire mimicry is waarschijnlijk cruciaal voor de inductie van anti-
ganglioside antistoffen. Of  deze kruisreagerende antistoffen worden geproduceerd is 
echter ook afhankelijk van andere factoren.
Mogelijk spelen erfelijke (genetische) factoren hierbij een rol. In dit proefschrift is 
onderzocht of  bepaalde genetische factoren een rol spelen bij het onstaan van GBS 
(susceptibiliteit) of  bij bepaalde klinische of  immunologische subgroepen van GBS 
patiënten. Het bestuderen van genetische factoren kan op twee manieren worden 
aangepakt: 1. Het bestuderen van families waarin meerdere leden GBS hebben 
doorgemaakt. 2. Het bestuderen van genetische variaties (polymorfismen) in genen die 
betrokken zijn bij de afweerreacties en het voorkomen van deze variaties te vergelijken 
tussen een groep GBS patiënten en gezonde controles (populatie associatie studies).
In Hoofdstuk 2 worden 12 Nederlandse families beschreven waarin minstens 2 
gevallen zijn van GBS. Het aantal gevonden families is te klein om te bewijzen dat 
GBS familiaal voorkomt. Het wat vaker voorkomen van GBS bij broers en zussen, het 
op jongere leeftijd ontstaan van GBS in opeenvolgende generaties en de ene patiënt 
die vier keer GBS heeft gehad, zijn wel suggestief  voor een bijdrage van genetische 
factoren aan het ontstaan van GBS.
In de Hoofdstukken 3-6 worden de genetische associatie studies beschreven die 
uitgevoerd zijn in een van werelds grootste groepen van goed gedocumenteerde 
GBS patiënten (n=272) waarbij een groep van gezonde bloedbank donoren (n=212) 
als controle groep fungeerde. Polymorfismen in diverse genen die een rol spelen in 
verschillende fasen van de afweerreactie zijn bestudeerd (in Appendix 2 staan alle 
bestudeerde polymorfismen opgesomd).
In Hoofdstuk 3 wordt beschreven of  functionele polymorfismen in de LPS 
receptoren CD14 en TLR4 geassocieerd zijn met een verhoogde kans op het krijgen 
van GBS of  met C. jejuni gerelateerde klinische en serologische kenmerken. Het 
C(-260)T polymorfisme in CD14 en de A(+896)G en C(+1196)T polymorfismen 
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in TLR4 bleken niet geassocieerd te zijn met een verhoogde kans op GBS of  met 
een verhoogde kans op het ontwikkelen van GBS na een C. jejuni infectie. Bovendien 
zijn deze polymorfismen niet geassocieerd met C. jejuni gerelateerde klinische en 
serologische subgroepen van GBS patiënten. Deze bevindingen duiden erop dat deze 
SNPs geen genetische gastheerfactoren zijn.
De distributie van HLA-DRB1 en HLA-DQB1 antigenen, die betrokken zijn bij 
antigeen presentatie voor antistof  responsen, werden vergeleken tussen GBS patiënten 
en controles (Hoofdstuk 4.1). De frequentie van deze antigenen in deze twee groepen 
verschilde niet van elkaar. Echter, de frequentie van het HLA-DR1 antigeen was 
verhoogd in de groep van beademende patiënten ten opzichte van de andere patiënten. 
In dit hoofdstuk hebben we alle eerder gepubliceerde HLA manuscripten onder de 
loupe genomen en geconcludeerd dat het polymorfe HLA systeem geen factor is die 
de kans op het krijgen van GBS bij alle patiënten verhoogd. Gegeven de gevonden 
associatie tussen HLA-DR1 en beademing bij GBS patiënten, zou het HLA systeem 
wel een modulerende rol kunnen spelen bij bepaalde subgroepen van GBS. 
Naast de presentatie van antigenen aan naïeve lymfocyten zijn ook co-stimulatoire 
signalen nodig om deze cellen te activeren. In Hoofdstuk 4.2 wordt bekeken of  
polymorfismen in genen coderend voor deze moleculen geassocieerd zijn met het 
krijgen van GBS of  met bepaalde subgroepen van GBS patiënten. Signalering via 
het CTLA-4 molecuul, één van de co-stimulatoire moleculen, oefent een remmende 
invloed uit op geactiveerde T-cellen. In de groep van mild aangedane GBS patiënten 
(F-score ≤ 2) werd een verhoogde frequentie van het T-allel op positie –318 in the 
promoter regio van CTLA4 en het T-318A+49 haplotype gevonden. Dit haplotype is 
waarschijnlijk geassocieerd met een hogere expressie van CTLA-4 en heeft daardoor 
mogelijk een remmende werking op het afweersysteem. Het T-allel op positie –1 van 
CD40, een molecuul betrokken bij B-cel activatie, is geassocieerd met de aanwezigheid 
van anti-ganglioside antistoffen en speelt mogelijk een rol bij de productie van deze 
antistoffen.
Hoofdstuk 5 wijdt zich aan SNPs in genen die coderen voor moleculen die betrokken 
zijn bij complement- en macrofaag gemedieerde zenuwschade. Het mannose-bindend 
lectine (MBL) herkent suiker groepen op het oppervlak van pathogenen en activeert 
daarna de lectine route van het complement systeem hetgeen leidt tot een verbeterde 
fagocytose. In Hoofdstuk 5.1 laten we zien dat de frequentie van het HYA haplotype 
dat geassocieerd is met de hoogste MBL concentraties, verhoogd is in de groep GBS 
patiënten, met name in de groep van patiënten met ernstige spierzwakte. De hoogste 
MBL concentraties en MBL complex activiteit zijn tevens geassocieerd met ernstige 
spierzwakte. Dit wijst erop dat hoge niveaus van functioneel MBL predisponeren voor 
het ontwikkelen van een ernstige vorm van GBS.
In Hoofdstuk 5.2 werd aangetoond dat de variant allelen van een SNP in de 
promoter regio van TNF-α (-863) en een SNP in de promoter regio van MMP-9 (-1562) 
geassocieerd zijn met ernstige spierzwakte. Deze moleculen worden uitgescheiden 
door macrofagen en zijn mogelijk betrokken bij de aantasting van de bloed-zenuw 
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barrière en het verergeren van weefselschade. 
Fas-FasL interacties spelen een belangrijke rol bij het induceren van apoptose, 
waardoor autoreactieve T en B cellen geëlimineerd kunnen worden. Bij patiënten 
met detecteerbare hoeveelheid anti-ganglioside antistoffen in het bloed komt het 
Fas promoter haplotype dat geassocieerd is met de laagste Fas expressie vaker voor 
(Hoofdstuk 6). Deze resultaten suggereren dat factoren die geassocieerd zijn met een 
verminderde apoptose tenminste deels de inductie van kruisreagerende antistoffen 
bepalen. 
Tenslotte worden in Hoofdstuk 7 de resultaten en hun bijdrage aan ziekte 
susceptibiliteit, antistof  productie, ernst en uitkomst van GBS bediscussieerd. Op 
basis van het onderzoek beschreven in dit proefschrift kan worden geconcludeerd dat 
er aanwijzingen zijn voor een rol van immuun respons genen in de pathogenese van 
GBS. Opvallend is dat er vooral een associatie is gevonden tussen bepaalde SNPs en 
de klinische manifestatie van GBS en niet ten aanzien van het ontstaan van GBS. Deze 
bevindingen zijn van belang om beter te kunnen begrijpen welke factoren bijdragen 
aan de ontwikkeling van een ernstige vorm van GBS. Toekomstig onderzoek zou zich 
kunnen richten op andere kandidaat-genen die bij kunnen dragen aan de ernst van de 
spierzwakte. Dit kan uiteindelijk leiden tot een betere voorspelling van de ernst van de 
ziekte, hetgeen mogelijk consequenties heeft voor de therapiekeuze en intensiteit van 
de in te stellen therapie. 
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List of abbreviations
AIDP   acute inflammatory demyelinating polyneuropathy
AMAN  acute motor axonal neuropathy
AMSAN  acute motor sensory axonal neuropathy
APC   antigen presenting cell
CD   cluster of  differentiation
C. jejuni   Campylobacter jejuni
CMV   cytomegalovirus
CSF   cerebrospinal fluid
CTLA-4  cytotxic T-lymphocyte antigen 4
EBV   Epstein-Barr virus
EMG   electrodiagnostic examination
FcγR   Fc gamma receptor
GBS   Guillain-Barré syndrome
HLA   human leucocyte antigen
IgA   immunoglobulin A
IgG   immunoglobulin G
IgM   immunoglobulin M
IL-10   interleukin 10
iNOS   inducible nitric oxide synthetase
IVIg   intravenous immunoglobulins
LOS   lipo-oligosaccharide
LPS   lipopolysaccharide
MFS   Miller-Fisher syndrome
MMP-9  matrix metalloproteinase-9
M. pneumoniae  Mycoplasma pneumoniae
MRC   Medical Research Council
NO   nitric oxide
PAI-1   plasminogen activator inhibitor 1
PRR   pathogen recognition receptors
RFLP   restriction fragment length polymorphism
SNP   single nucleotide polymorphism
TLR-4   toll-like receptor 4
TNF-α   tumor necrosis factor alpha
URTI   upper respiratory tract infection 
UTR   untranslated region
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Appendix 1: Diagnostic criteria of Guillain-Barré syndrome
Features required for the diagnosis
- Progressive motor weakness of  more than one limb
- Areflexia or marked hyporeflexia in very weak muscles (<grade 3 MRC)
Features strongly supportive of the diagnosis
- Progression over days to a maximum of  four weeks
- Relatively symmetry
- Mild sensory signs or symptoms
- Cranial nerve involvement
- Onset of  recovery 2-4 weeks after progression stops
- Autonomic dysfunction
- Initial absence of  fever
- Elevated CSF protein after the first week of  symptoms
- CSF cell counts of  10 or fewer mononuclear leucocytes/mm3
- Abnormal electrodiagnostics with conduction slowing or block
- No other identifiable cause
Features that rule out the diagnosis
- A current history of  hexacarbon use
- Abnormal porphyrin metabolism
- A history or finding of  recent diphtheric infection
- Lead intoxication
- The occurrence of  a purely sensory syndrome
- Diagnosis of  poliomyelitis, botulism, hysterical paralysis or toxic neuropathy
Adapted from the revised version of  the diagnostic criteria for GBS, set up by the 
National Institute of  Neurological Disorders and Stroke. Asbury AK, Cornblath DR. 
Assessment of  diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990 
(suppl);27:21-24.
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Appendix 2. List of polymorphisms studied.
Gene  SNP  chromosome region  functional effect on
pattern recognition receptors
CD14 C(-260)T 5q31.1 CD14 expression
TLR4 A (+896)G 9q32-q33 amino acid substitution 
extracellular region
        C (+1196)T
MBL2 H (-550)L 10q11.2-q21 transcriptional regulation
X (-221)Y transcriptional regulation
codon 52 (D) protein function
codon 54 (B) protein function
codon 57 (C) protein function
Antigen presentation
and costimulation
HLA HLA-DRB1 6p21.3 binding peptide
HLA-DQB1 6p21.3
CD28 IVS3+ 17T/C 2q33 splicing?
CD86 G(+864)A 3q21 intracellular signaling?
CTLA4 C(-318)T 2q33 transcriptional activation 
A(+49)G amino acid substitution in peptide 
leader sequence
CD40 -1 C/T 20q12-q13.2 efficiency translation
CD40L C(-726)T Xq26 not known
C (+221)T not known
ICAM1 G241R 19p13.3-p13.2 binding capacity ligand
E469K cell adhesion and costimulation
Complement and macrophage 
mediated damage
complement activation
MBL2 H (-550)L 10q11.2-q21 transcriptional regulation
X (-221)Y transcriptional regulation
codon 52 (D) protein function
codon 54 (B) protein function
codon 57 (C) protein function
cytokines
TNF-α C(-863)A 6p21.3 transcriptional regulation 
G(-308)A
G(-238)A
IL-10 G(-1082)A 1q31-q32 transcritpional regulation 
C(-819)T
pro-inflammatory mediators
MMP-9 C(-1562)T 20q11.2-q13.1 transcritpional regulation
PAI-1 4G/5G (-504) 7q21.3-q22 PAI-1 production
iNOS S(608)L 17cen-q11.2 amino acid substitution
Apoptosis
Fas G(-1377)A 10q24.1 transcriptional regulation
A(-670)G
FasL  C(-843)T  1q23  transcriptional regulation
TLR4: Toll-like receptor 4, MBL2: Mannose-binding lectin, HLA: Human Leucocyte antigen, CTLA4: Cytotxic T 
lymphocyte antigen-4, TNF-α: Tumor necrosis factor-alpha, IL-10; interleukin 1, MMP-9: matrix metalloproteinase 9, 
PAI-1: plasminogen activator inhibitor-1, iNOS: inducible nitric oxide synthetase    
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Dankwoord
Eindelijk het boekje is af! Een groot aantal mensen heeft de afgelopen jaren 
bijgedragen aan het tot stand komen van dit boekje. De deelname van patiënten aan 
het onderzoek was een onmisbare eerste stap binnen mijn onderzoek. Vele patiënten, 
en soms ook familieleden, hebben deelgenomen aan de studie, waarvoor ik hen wil 
bedanken. Binnen het project zijn er veel samenwerkingsverbanden geweest tussen 
afdelingen binnen het Erasmus MC, maar ook met afdelingen buiten de muren van dit 
medisch centrum. Een aantal mensen wil ik op deze plaats persoonlijk bedanken.
De eer om als eerste bedankt te worden gaat natuurlijk uit naar mijn promotor 
prof. dr. P.A. van Doorn. Beste Pieter, jouw enthousiasme en klinische blik zijn erg 
waardevol geweest tijdens mijn onderzoek. Elk artikel voorzag jij van commentaar 
opdat ook de clinicus pur sang nog geïnteresseerd zou zijn in mijn publicaties. 
Bovendien was jij bij congressen de persoon bij uitstek die het nuttige met het 
aangename wist te combineren. 
Binnen het onderzoek werd ik verder begeleid door dr. J.D. Laman en dr. B.C. Jacobs, 
die op deze dag als copromotoren zullen optreden en terecht. Beste Jon, jouw kritische 
blik op doel, vraagstelling en opzet van experimenten hebben zeker bijgedragen aan 
de vorming van een wetenschapper. Beste Bart, na een jaartje of  twee kwam jij als 
frisse wind binnen het onderzoek. Jouw ideeën over GBS, jouw heldere manier van 
uiteenzetten en structureren van artikelen zijn van grote klasse. 
Als AIO had ik de enorme luxe om door 2 goede analisten ondersteund te worden. 
Beste Anne, aan jouw nauwkeurigheid en systematiek kan wat mij betreft echt niemand 
tippen! Beste Wouter, jouw doorzettingsvermogen en je nooit aflatende vrolijkheid 
bij het zoveelste LightCycler experiment of  zelfs bij de oude RFLP-techniek waren 
van grote klasse. Ik ben jullie beide dan ook erg dankbaar voor jullie inzet en het 
afgeleverde werk!
Gedurende de periode mocht ik ook een aantal maanden een stagiaire begeleiden. 
Lieve Brigitte, het was een waar feest om jou te mogen begeleiden. Stad en land heb je 
afgereisd om families in kaart te brengen. Helaas zat het tripje naar Engeland er niet 
meer in!
Daarnaast wil ik nog een aantal mensen bedanken die mij bij verschillende artikelen 
met raad en daad hebben bijgestaan. Dr. J.J. Houwing-Duistermaat, beste Jeanine, als 
eerste wil ik jou bedanken voor je begeleiding op het gebied van de statistiek. Je hebt me 
geleerd dat statistiek leuk en inzichtelijk kan zijn!  Dr. Kees Sintnicolaas en dr. Wilfried 
Levering bedank ik voor het beschikbaar stellen van genomisch DNA van gezonde 
bloedbank donoren, wat mij een hoop verzameltijd en isolaties gescheeld heeft, en 
natuurlijk voor de HLA-typeringen. Kennis en inzicht van het zeer polymorfe HLA-
systeem werden mij bij gebracht door dr. G.M.Th Schreuder. Beste Ieke, ik dank je 
voor jouw tijd, kennis en enthousiasme. Geert Haasnoot, de “HLA-statisticus” wil ik 
om dezelfde redenen bedanken. Prof. dr. C.M. van Duijn, beste Cock, dankjewel voor 
jouw inbreng in het familie-onderzoek. Binnen het MBL project heb ik uitgebreid 
kunnen overleggen met de Leidse onderzoeksgroep van de Nefrologie. Dr. A. Roos, 
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beste Anja, bedankt voor jouw inzet, kennis en enthousiasme omtrent het MBL-
onderzoek. De dagen op jullie lab waren een aangename afwisseling, waarvoor ik ook 
Maria Borrias dank verschuldigd ben. Binnen het Erasmus MC is een afdelingsbreed 
polymorfismen project opgezet waarbij drs. M. Emonts en dr. P.W.M. Hermans 
een drijvende kracht vormen. Beste Marieke en Peter bedankt voor de prettige 
samenwerking.
Naast de artikelen is het bij een proefschrift ook van belang dat het 
boekje er goed verzorgd uitziet. Erna Moerland-van Eenennaam en Marcia 
IJdo-Reintjes bedank ik voor het lay-outen (wat een haastklus was) en 
Tar van Os voor de mooie figuren en de snelle hulp bij mijn kaftontwerp.
 Naast alle mensen die direct bijgedragen hebben aan de artikelen en het boekje zijn 
er nog veel meer mensen die het werken hebben veraangenaamd. Het project heeft 
zich grotendeels afgespeeld op twee verschillende afdelingen wat zo zijn voor- en 
nadelen heeft. Het voelde af  en toe alsof  ik een soort zwervend bestaan had, maar 
gelukkig waren er vaste elementen in dit bestaan.  Allereerst waren daar alle Guillain-
Barré onderzoekers.  Liselotte, Marcel, Mark, en Rinske bedankt voor jullie gezellige 
verhalen, de prettige samenwerking, de  leuke congressen,  maar ook voor de peptalks 
tijdens de bekende AIO-dips. Alle oude en nieuwe collega’s op de 22e (Annemarie, 
Bas, Dirk, Dragan, Eric, Evy, Hanneke, Ilse, Joke, Karin, Kris, Laura, Lisette, Maaike, 
Marie-Claire, Mary-Lou, Nadine, Nazia, Rinze, Rita en Sonia), de collega’s van “de 
sleuf ” (Annette, Debby, Fleur, Grietje, Jane, Leontien, Leslie, Lisette, Lizette, Marie-
José, Marjan, Marloes, René en Sabine) en  de AIO’s van de Immunologie wil ik 
bedanken voor de prettige werksfeer.  Ook mijn nieuwe collega’s in de kliniek dank ik 
voor de prettige werksfeer, de collegialiteit en hun flexibiliteit waardoor het mogelijk 
was om in die drukke eerste periode én te wennen in de kliniek én ook nog eens aan 
mijn boekje te werken.
Verder is er gelukkig naast het werkende leven ook nog tijd voor een privé leven.
Bij een promotie horen twee paranimfen! Beste Hugh en Floris, wat heerlijk om op de 
grote dag jullie naast me te hebben staan. Beide kennen jullie het klappen van de zweep 
in onderzoeksland, alhoewel Floris besloten heeft om nu niet te gaan promoveren en 
Hugh daar een hele eigen draai aan heeft gegeven. Ik weet zeker dat ik me naast jullie 
erg op me gemak zal voelen en jullie mij, indien nodig, van de nodige peptalks zullen 
voorzien. 
Lieve vrienden, ook al worden jullie pas aan het einde van het dankwoord genoemd, 
jullie vriendschap is voor mij ontzettend belangrijk! Wat zou het leven saai zijn geweest 
zonder jullie aanwezigheid! Het lachen, het luisteren, de gesprekken, de wandelingen, 
het roeien ....dat wil ik nooit missen!!!
Lieve paps & mams, lieve Erik & Nathalie ondanks dat jullie soms vraagtekens 
zetten bij mijn lange weg op de universiteit en door onderzoeksland, hebben jullie mij 
altijd gesteund. Jullie liefde is waardevol voor mij!
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